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Abstract

In the United States, prostate cancer is the second most common reason
for cancer death in men. No imaging methods currently exist which are specific
for detecting, imaging, and treating extracapsular or metastatic prostate cancer.
The goal of this research was to develop novel nanoparticles that would
specifically target human prostate cancer cells and simultaneously deliver a
chemotherapeutic agent and superior magnetic resonance imaging (MRI)
contrast agent to the prostate cancer cells for both therapy and MRI detection.
This dissertation describes the synthesis and comprehensive characterization of
superparamagnetic iron-platinum nanoparticles (SIPPs) and their subsequent
encapsulation with the drug Paclitaxel, using a mixture of functionalized
phospholipids, to create SIPP and Paclitaxel-loaded micelles (SPMs) conjugated
to an antibody against prostate specific membrane antigen (PSMA), which is
specifically over-expressed in human prostate cancer cells and tumors. Taken
together the data suggest that SPMs specifically target human prostate cancer
cells, are superior contrast agents in T2-weighted MRI, and prevent prostate
tumor growth in a PSMA-dependent manner.
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Chapter 1
Introduction

Prostate Cancer
Prostate cancer is the most common non-skin cancer and the second leading
cause of cancer death in men in the United States (1). Prominent, unresolved
problems with the clinical management of prostate cancer include the lack of
highly specific detection methods and efficient therapeutic interventions. Serum
prostate specific antigen (PSA) measurements are widely used to infer the
presence of disease, yet elevated PSA concentrations can also result from
benign prostatic hyperplasia (BPH) suggesting that these measurements lack
specificity (2).

Elevated serum PSA concentrations are often followed by

invasive biopsies in an attempt to discover, grade and stage prostate cancer,
however, the results from the European Randomized Study of Screening for
Prostate Cancer showed that 75% of PSA-driven biopsies are negative (3,4).
These results are congruent with previous studies that reported false-negative
biopsy rates of 30-50% in patients with subsequently-confirmed small and
inconspicuous malignant lesions (5). Twenty to forty percent of patients initially
responding to treatment by androgen ablation, prostatectomy or radiation,
relapse and ultimately progress to castration resistant disease (6). After relapse,
subsequent chemotherapeutic options are limited, inefficient, and plagued by
side effects due to lack of specificity (7). Even patients treated by surgical
resection, with clean margins, of organ-confined prostate cancer carry a 25 %
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lifetime risk of mortality from metastases, while 40 % of the surgically-resected
prostate tumors are restaged upwards by the pathologist, indicating that the initial
staging was inaccurate. Although sophisticated nuclear magnetic resonance
(NMR) spectroscopic imaging methods can aid tumor detection for organconfined disease (8) the vast majority (>90%) of prostate cancer mortality
involves disseminated, metastatic disease. No imaging method currently exists
which is specific for detecting and staging extracapsular or metastatic prostate
cancer.

Prostate cancer targets
The specific targeting of cancer cells has become a unifying theme
driving the development of novel imaging and therapy modes (9). Targeting
motifs are often antibodies or peptides directed against antigens specifically
expressed on malignant cells and not expressed on healthy cells. The targeting
of over-expressed membrane proteins on prostate cancer cells, using innovative
therapeutic and diagnostic methods, promises to increase the specificity of
prostate tumor diagnosis and treatment (10,11) while potentially increasing the
efficacy and decreasing the side-effects (12,13). The most promising prostate
cancer target antigen is prostate specific membrane antigen (PSMA), whose
expression is mainly limited to the prostate and has been found to increase as
tumor grade increases (14). Thus, antibodies against PSMA are an appealing
choice for use as targeting motifs specific for prostate cancer. In addition to overexpression on the cell surface of both primary and metastatic prostate cancer
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cells, high PSMA expression has been reported in the neovasculature of most
solid tumors, but not in healthy vasculature (15), suggesting that PSMA may also
be a general tumor antigen that could be used to detect numerous types of
cancer. Prior research by ourselves and others (16-18) has demonstrated the
successful targeting of cancer.

We have shown, for example, that agents

conjugated to a monoclonal antibody against PSMA, specifically bind to PSMApositive prostate cancer cells in vitro (19). Although PSMA is a prime target for
prostate cancer, there are other possible targets. Three other membrane-bound
proteins that are over-expressed in prostate cancer and implicated in cancer
progression include the integrin !"#3, the neurotensin receptor 1 (NTSR1), and
prostate stem cell antigen (PSCA) (2, 20-23).

Nanoparticles for cancer imaging and therapy
Superparamagnetic nanoparticles are superior platforms for both the
detection

and

delivery

of

therapeutics

to

tumors

because

they

can

simultaneously carry drugs and be observed using magnetic resonance imaging
(MRI) (24). Exciting early developments in nanoparticle research (25-29)
supported the possibility of producing magnetic imaging agents which were
exquisitely specific for prostate cancer cell surface markers and could be used
for the detection of both primary and metastatic disease. For example, Artemov
et al. (30,31) successfully targeted superparamagnetic iron oxide nanoparticles
(SPIONs) to the Her-2 receptor in breast cancer cells and detected the SPIONs
by MRI. Although SPIONs have been most commonly used in contrast agent-
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enhanced MRI to date, they are not necessarily optimal.

Nanoparticles with

increased MR relaxivities would increase the contrast enhancement in MRI for
various medical conditions including cancer. Towards this goal, our work has
focused on the development of novel, superior, targeted nanoparticles as MRI
and drug delivery agents for improved imaging and therapy of prostate cancer.
We chose to investigate the production of iron platinum (FePt)
nanoparticles due to their higher magnetic anisotropy and stability compared with
iron oxide (32-36). Much of the research on FePt has been directed towards
producing ferromagnetic face-centered tetragonal (fct) particles, for use in
magnetic storage devices, by annealing superparamagnetic face-centered cubic
(fcc) nanoparticles at temperatures exceeding 500 °C (36-39). However, fcc
Superparamagnetic Iron Platinum nanoParticles (SIPPs) are of interest by
themselves due to their potential as contrast agents in MRI (40-42).

For

superparamagnetic MRI contrast agents, a higher magnetic moment at a given
magnetic field causes larger perturbations in the magnetic relaxation times of
nearby water protons and, thus, higher moment particles generate increased
image

contrast.

SIPPs

have

previously

been

reported

with

volume

magnetizations approaching 1,140 emu/cm3 (1 x 106 A/m), the saturation
magnetization of bulk FePt (43-46). These high reported magnetic moments
suggested that SIPPs would be superior MRI contrast agents.
SIPPs offer significant advantages over other potential contrast agents in
that they have very large magnetic effects, which are propagated over long
distances, due to their extremely large induced magnetic moments.
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surrounding water molecules, in the case of MRI, act as signal amplifiers and
detectors for the magnetic field gradients induced by the nanoparticles.
Alternatively, direct detection of the nanoparticles can be accomplished with the
extremely sensitive superconducting quantum interference devices (SQUIDs)
now available (5, 6).
Currently, clinically approved MRI contrast agents are limited to
gadolinium chelates or liver-targeted iron oxide contrast agents (7).

The

gadolinium-based MR agents can discriminate between diseased and healthy
tissues to some extent (8) but their specificity can be improved through targeting
(9-12) using ligands with specific binding capabilities, such as prostate specific
antibodies. Injected intravenously, SPIONs slowly extravasate from the vascular
into the interstitial space, where they travel through the interstitial-lymphatic fluid
to target small nodal metastases (13). A dextran coating on the iron oxide core
prolongs their lifetime in the circulation, an advantage over gadolinium chelates,
which generally undergo rapid renal elimination (14). Additionally, polyethylene
glycol (PEG) groups on nanoparticles have been shown to increase solubility and
circulation times and decrease immunogenicity (47, 48).

This decrease in

immunogenicity imparts the nanoparticles a stealth capability in vivo. A plethora
of methods for biocompatibly-encapsulating drugs and hydrophobic imaging
agents have been reported and include encapsulation using hydrophilic or
amphiphilic

components

such

as

monomers

and

phospholipids

(47).

Furthermore, biocompatible contrast agents that also incorporate a fluorescent
component offer the advantage of in vivo and ex vivo imaging using small animal
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fluorescence imagers and/or fluorescence microscopy for in vivo biodistribution
studies and in vitro binding assays.

Hypothesis
In 2011, more than 200,000 men were newly diagnosed with and over
30,000 men died due to prostate cancer in the United States, making carcinoma
of the prostate the second most lethal cancer in men in the United States (49).
New detection methods are critically needed to achieve earlier diagnosis and
better staging of the disease.

SPION contrast agents have been used to

enhance the contrast of tumors in MRI, but novel contrast agents with increased
relaxivities would be useful in detecting smaller tumors earlier and with lower
doses of the contrast agents.

Additionally, the specific targeting of contrast

agents and therapeutics to cells of interest is now widely accepted as a
cornerstone to the development of individualized diagnosis and treatment.
Therefore, the hypothesis of this dissertation is that SIPPs and a hydrophobic
chemotherapeutic drug, Paclitaxel (PTX), encapsulated in a mixture of
polyethylene glycol (PEG)-, fluorescent-, and biotin-functionalized phospholipids
and conjugated to a monoclonal antibody against PSMA would specifically target
prostate cancer cells, be superior MRI contrast agents for prostate cancer
detection (compared to SPIONs), and have increased therapeutic efficacy in vivo
compared to Paclitaxel alone.
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Specific Aims
Specific Aim 1: Previous studies, including our own, demonstrated that PSMAtargeting can be successfully used to direct SPIONs to human prostate cancer
cells in vitro. Although these studies provided strong evidence that PSMA was a
good target to use, they did not address the possibility that other membrane
receptors might be equally useful and highly expressed on prostate cancer cells.
More importantly, the prior studies did not address the expression of PSMA or
other membrane receptors in vivo. From the translational standpoint, it is of vital
importance to ensure that in vitro successes can also be achieved in an in vivo
model to allow for the highest possible probability of clinical success. It is not
uncommon to encounter difficulties either when translating in vitro applications to
pre-clinical models or when moving such applications to clinical usage.
Therefore, specific aim one (addressed in Chapter 2) was to measure, in vitro
and in vivo, mRNA and protein expression of several different membrane
receptors, including PSMA, in multiple human prostate cancer cell lines and
xenografts to determine the best cell line to use for testing targeted nanoparticles
both in vitro and in vivo.

Specific Aim 2: One drawback to the synthesis of various types of nanoparticles
is that toxic precursors are generally used to produce the particles (35, 36, 50).
Often, iron pentacarbonyl, Fe(CO)5, a very hazardous reagent (51), has been
used as the iron precursor in FePt syntheses (36). A number of different FePt
syntheses are described by Sun (35). Recently, Zhao et al. (44) described a
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method for producing ~11 nm SIPPs using the hydrophobic surface ligand 1octadecylamine (ODA) along with iron and platinum salts that were much less
hazardous than Fe(CO)5. Although the authors used this synthetic method to
synthesize SIPPs using these “greener” methods, they did not optimize these
particles for MRI and did not fully characterize the structural and magnetic
properties of their particles. Therefore, specific aim two (addressed in Chapter 3
and 4) was to synthesize SIPPs and characterize their structural and magnetic
properties, compared to SPIONs.

Specific Aim 3: Typical syntheses of superparamagnetic nanoparticles are
performed at high temperatures in organic solvents to produce very hydrophobic
nanoparticles that are stored in solvents such as hexane or chloroform. In order
to use these particles for biological applications, the hydrophobic core particles
must be made biocompatible (hydrophilic) so that they can be injected into the
blood. Additionally, the particles must be modified in such a way so that longer
circulation times and decreased immunogenicity can be achieved. Moreover, the
particles must be functionalized so that antibodies and/or peptides can be
conjugated to their surface to specifically target the particles to the cell of choice.
Therefore, specific aim three (addressed in Chapter 4 and 5) was to encapsulate
SIPP cores and PTX in a mixture of fluorescent- and biotin-functionalized
PEGylated phospholipids, to conjugate a monoclonal antibody against the best
single membrane receptor determined in Aim 1, and to measure their structural
and magnetic properties, drug loading, drug release rates, in vitro cytotoxicity,
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and specific binding to human prostate cancer cell lines.

Specific Aim 4: As stated earlier, it is not uncommon for promising in vitro
success with novel nanoparticles or treatments to fail in animals or humans.
Therefore, specific aim 4 (addressed in Chapter 5) was to quantify the
therapeutic response to the particles, biodistribution, and MRI contrast
enhancement in athymic nude mice bearing human prostate cancer xenografts.
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Abstract
Background: Membrane receptors are frequent targets of cancer therapeutic
and imaging agents. However, promising in vitro results often do not translate to
in vivo clinical applications. To better understand this obstacle, we measured the
expression differences in receptor signatures among several human prostate
cancer cell lines and xenografts as a function of tumorigenicity.
Methods: Messenger RNA and protein expression levels for integrin !"#3,
neurotensin receptor 1 (NTSR1), prostate specific membrane antigen (PSMA),
and prostate stem cell antigen (PSCA) were measured in LNCaP, C4-2, and PC3 human prostate cancer cell lines and in murine xenografts using quantitative
reverse

transcriptase

polymerase

chain

reaction,

flow

cytometry,

and

immunohistochemistry.
Results: Stable expression patterns were observed for integrin !" and PSMA in
all cells and corresponding xenografts. Integrin #3 mRNA expression was greatly
reduced in C4-2 xenografts and greatly elevated in PC-3 xenografts compared
with the corresponding cultured cells. NTSR1 mRNA expression was greatly
elevated in LNCaP and PC-3 xenografts. PSCA mRNA expression was elevated
in C4-2 xenografts when compared with C4-2 cells cultured in vitro.
Furthermore, at the protein level, PSCA was re-expressed in all xenografts
compared with cells in culture.
Conclusions: The regulation of mRNA and protein expression of the cell-surface
target proteins !"#3, NTSR1, PSMA, and PSCA, in prostate cancer cells with
different

!

tumorigenic

potential,

was

%)!

influenced

by

factors

of

the

!

microenvironment, differing between cell cultures and murine xenotransplants.
Integrin !"#3, NTRS1 and PSCA mRNA expression increased with tumorigenic
potential, but mRNA expression levels for these proteins do not translate directly
to equivalent expression levels of membrane bound protein.
Keywords: !"#3, NTSR1, PSCA, PSMA, tumorigenic potential, cells versus
xenografts, membrane proteins

Introduction
Prostate cancer is the second most common cancer and the second
leading cause of cancer death in men in the United States (1). Prominent and
unresolved problems with the clinical management of prostate cancer include the
lack of highly specific detection methods and efficient therapeutic interventions.
Serum prostate specific antigen (PSA) measurements have been used as a
measure of the presence of disease, yet abnormal PSA levels can also result
from benign prostatic hyperplasia (BPH), and other non-malignant processes,
indicating that PSA measurements lack specificity (2).

Biopsies are

recommended if abnormal PSA levels are found, but results from the European
Randomized Study of Screening for Prostate Cancer imply that there is around a
75% negative biopsy rate using PSA as a diagnostic marker (3,4). These results
confirm previous studies that reported a 30-50% false-negative biopsy rate in
patients with subsequently confirmed malignancy due to small and inconspicuous
lesions (5). Twenty to 40 per cent of prostate cancer patients initially responding
to treatment by androgen ablation, prostatectomy or radiation, relapse and
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ultimately

progress

to

castration

resistant

disease

(6).

Subsequent

chemotherapeutic options are limited, often inefficient, and prone to side effects
due to lack of specificity (7).
The specific targeting of cancer cells has become a unifying theme
supporting the development of novel imaging and therapy modes (8). Often, the
targeting molecules are antibodies, or peptides, which bind to cell-surface
membrane proteins that are specifically-, or over-expressed on malignant cells
but not expressed on healthy cells. These innovative targeted therapeutic and
diagnostic methods promise to increase both the specificity and efficacy of
prostate tumor diagnosis and treatment (9,10) while reducing the side-effects
(11,12).
Monofunctional, targeted nanoparticles were developed as magnetic
resonance imaging (MRI) and drug delivery agents for detection and therapy of
prostate cancer (13).

These superparamagnetic iron oxide nanoparticles

(SPIONs) and superparamagnetic iron platinum particles (SIPPs), when
conjugated to a monoclonal antibody against prostate specific membrane antigen
(PSMA), specifically bound to PSMA-positive prostate cancer cells in vitro and
generated contrast enhancement in MR images (13). While monofunctional
nanoparticles performed well, it was reasonable to expect that the efficacy of
imaging and therapeutic agents could be improved by using multiple targeting
motifs on a single nanoparticle, because this would markedly increase the affinity
of the nanoparticles for their targets.

Furthermore, such a multifunctional

approach might be required in order to detect and treat advanced tumors that are
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characterized by increased heterogeneity of target antigen expression (2).
Imaging and therapeutic agents simultaneously directed to multiple targets
expressed by cancer cells should show increased affinities, effectiveness, and
specificities when compared with monofunctional agents.

These targeting

strategies can be tested in suitable prostate cancer cell models with wellcharacterized phenotypes, such as the human cell lines LNCaP, C4-2, and PC-3,
which feature increasing tumorigenic potential and are widely-used in basic and
pre-clinical research (13,14). The androgen dependent LNCaP cells were
originally isolated from a lymph node metastasis, but are non-aggressive in in
vitro assays and have low tumorigenicity in vivo (13).

The C4-2 cells are

derivatives of LNCaP cells that were passaged in castrated mice, a procedure
rendering them androgen-independent, and more-invasive, characteristics
associated with human progressive prostate cancer and moderate tumorigenicity
(13).

The androgen-independent PC-3 cells were isolated from a bone

metastasis in a patient with castration-resistant prostate cancer (CRPC) and
consequently display a high tumorigenic potential (13). In order to use these
cells for the development of multi-targeted imaging or therapeutic agents, it was
important to characterize their membrane antigen expression profiles (membrane
receptor signatures) with respect to potential targeting motifs. In the present
study, we measured the mRNA and cell-surface protein expression profiles for
four membrane bound proteins that are over-expressed in prostate cancer and
implicated in cancer progression (2,15-18). These cell-surface proteins included
the integrin !"#3, the neurotensin receptor 1 (NTSR1), PSMA, and prostate stem
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cell antigen (PSCA) in LNCaP, C4-2, and PC-3 cells. Furthermore, because
promising in vitro results with cells often do not translate in vivo to similar results
in tumors, we determined the differences in the expression of these receptors
between cells cultured in vitro as opposed to cell deposits grown as xenografts in
immunocompromised mice in vivo.
This study provides an, as yet unreported, overview of the expression
signatures for membrane receptors with targeting potential in prostate cancer
cells.

Knowledge generated in this study should provide further guidance in

assessing the utility of cell lines, animal models, and surface markers for
targeting purposes in prostate cancer research. Caution should be exercised
when it is assumed that the same cell-surface markers are present on cells and
xenografts from these same cells.

Materials and Methods
Materials
The prostate cancer cell lines LNCaP and PC-3 were purchased from the
American Tissue Type Collection (Manassas, VA, USA).

The C4-2 prostate

cancer cell line was a kind gift from Dr. G.N. Thalmann (University of Bern,
Switzerland). Anti-PSMA, clone J591 antibody was purchased from Neil H.
Bander, MD (Cornell College of Medicine, USA).

FITC-labeled mouse IgG1

control antibody was obtained from BD Biosciences (San Jose, CA, USA). FITClabeled mouse anti-PSMA IgG1, clone 107-1A4 antibody was obtained from
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Medical & Biological Laboratories Co., Ltd. (Woburn, MA, USA). FITC-labeled
mouse anti-PSCA IgG1, clone 7F5 and mouse anti-NTSR1 IgM antibodies were
obtained from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). FITClabeled mouse anti-CD51/61 IgG1, clone 23C6 and FITC-labeled rat anti-mouse,
clone RMM-1 antibodies were obtained from Biolegend (San Diego, CA, USA).
Quantum Simply Cellular anti-Mouse IgG-Medium Level epitope-density
calibration beads were obtained from Bangs Laboratories, Inc. (Fishers, IN,
USA).

All other chemicals and supplies were purchased from common

manufacturers.

Cell Culture
All cell lines were cultured on 75 mm plastic plates in T-medium with 10%
FCS (19) at 37 °C in a humidified, 5% CO2 atmosphere. Upon reaching 90%
confluency, cells used for qRT-PCR were detached from the plates with the aid
of a 0.5% trypsin solution containing 0.02% EDTA, collected with centrifugation
at 700 rpm and stored at -80 °C in PBS. Cells used for flow cytometry were
released using 5.0 mM EDTA and pipetted to form a monodisperse suspension.
Cells were then washed with PBS, and immediately used.

Xenograft Production
The University of New Mexico Institutional Animal Care and Use
Committee approved all experiments involving animals. Three million LNCaP,
C4-2, or PC-3 cells in 1:1 (vol/vol) BD MatrigelTM (BD Biosciences, San Jose, CA,
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USA) were injected into the right flank of 5-8 week old athymic nude male mice
(Harlan Sprague Dawley, Frederick, MD, USA). Once the tumors had reached a
volume of ~100 mm3, the mice were euthanized using CO2 asphyxiation. For
qRT-PCR, the tumors were excised, flash frozen in liquid nitrogen, and stored at
-80 °C. For immunohistochemistry, tumors were excised and fixed in 10%
buffered formalin.

Flow Cytometry
The Mean Channel Fluorescence (MCF) of cells stained with fluoresceinisothiocyante-, (FITC)-, labeled IgG1 antibodies was compared with a standard
curve generated using the appropriate IgG1 corrected for the IgG1 control
fluorescence. The epitope-density calibration beads and 105 cells were stained
separately by the addition of 15 µl of the appropriate antibody or control antibody
in 100 µl Phosphate Buffered Saline (PBS). Cells and beads were incubated in
the dark at room temperature for 15 minutes, washed once with PBS, and
resuspended in 200 µl PBS. The calibration beads and cells were analyzed using
FL1 on a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA).
IgG1 antibodies against all epitopes were available, except for those against
NTSR1, which were only of the IgM class.
Since the epitope-density calibration beads were specific for IgG
antibodies, and could not be used for the NTSR1-directed IgM antibodies, we
compared the MCF of the cells stained for NTSR1 with that of the secondary
antibody alone. One hundred thousand cells were stained by the addition of 15 µl
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of NTSR1 IgM antibody in 100 µl PBS. Cells were incubated in the dark at room
temperature for 15 minutes, washed once with PBS, and resuspended in 100 µl
PBS. Fluorescent staining was performed by adding 15 µl of FITC-labeled antimouse antibody to the labeled and control, unlabeled cells. These samples were
incubated in the dark at room temperature for 15 minutes, washed once with
PBS, and resuspended in 200 µl PBS. The calibration beads and cells were
analyzed using FL1 on a FACSCalibur flow cytometer (BD Biosciences, San
Jose, CA, USA).

Messenger RNA (mRNA) Expression Analysis by Quantitative Real Time
Reverse Transcriptase Polymerase Chain Reaction (qRT-PCR)
Baseline expression of !", #3, NTSR1, PSMA, and PSCA was determined
by qRT-PCR. Cultured cells were recovered as explained above. Tissues (0.10.5 mg) were immediately frozen in liquid nitrogen upon resection from the
animals and subjected to complete homogenization (15-100 seconds) in
isothiocyante containing chaotropic buffer (Qiagen, Valencia, CA, USA) using a
rotor-stator homogenizer. Total RNA was extracted using RNEasy kits from
Qiagen (Valencia, CA, USA) according to the manufacturer’s protocols, and
analyzed for concentration and purity using a Nanodrop spectrophotometer
(Thermo Scientific, Wilmington DE, USA). The integrity of the 5 S, 18 S, and 28 S
ribosomal RNAs was examined using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA). Complementary DNA (cDNA) was
prepared using the RETROscript cDNA synthesis kit from Ambion (Austin, TX,
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USA) using random decamer primers in the presence of an RNase inhibitor
(Promega, Madison, WI, USA). TaqMan qRT-PCR was performed using a Roche
480 Light Cycler (Roche, Indianapolis, IN, USA). Primers and probes were
designed using sequence information from the National Center for Biotechnology
Information (NCBI) and Primer Express Software (Applied Biosystems, Carlsbad,
CA, USA). The sequences of the primers and probes are given in Table 2.1.
Five hundred nanograms of cDNA were used per reaction in a total volume of 25
µl of Taq Plus PCR Master Mix (Qiagen, Valencia, CA, USA) containing 900 nM
of the primers and 300 nM of the probes.

Table 2.1 Primers and probes used for qRT-PCR
Receptor

Primer Sequence (5’ > 3’)

Probe1 (5’ > 3’)

!"

F- TTCCCTTCCGGGTAGACG TA
R- TGTGCAAAAATAATGCTCTTCGTAT
F- TTTACCACTGATGCCAAGACTCA
R- CCGTCATTAGGCTGGACAAT
F- GGCGCCTCATGTTCTGCTA
R- GTGCGTTGGTCACCATGTAGA
F- CAGGACTACTACGTG GGCAAGA
R- CGCTGGCGTTGCACAA
F- GCTGATAAGCGAGGCATTAGT
R- TGCGCGCCCTCCAA

TGCTGGATAAACACAAGC
AAAAGGGAGC
CATTGGACGGAAGGCTGG
CAG
ATGAGCAGTGGACTCCGT
TCCTCTATGACTTCT
AACATCACGTGCTGTGAC
ACCGA
AGACTTTACCCCGCCGTG
GTG

#3
NTSR1
PSCA
PSMA
1

All probes had a 5’-56-FAM fluorophore and a 36-TAMSp-3’ quencher
The cycling conditions were 95°C 10 min, 45x (95°C 15 sec, 60°C 1 min).

No-template and non-reverse-transcribed RNAs were used as controls. All
reactions were run in triplicate. Signals for !", #3, NTSR1, PSMA, and PSCA were
normalized to RNA input using the signals from TATA binding protein (TBP). The
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expression differences were calculated by the 2-!!Ct method for assessing relative
expression.

Immunohistochemistry
Formalin-fixed tumors were paraffin-embedded and stained by Tricore
Reference Laboratory (Albuquerque, NM, USA) using an automated procedure
with a Ventana BenchMark XT IHC/ISH Staining Module and polyclonal rabbit
anti-human PSCA antibody (Invitrogen, Carlsbad, CA, USA).

Results
Messenger RNA and protein expression levels for integrin !"#3, NTSR1,
PSMA, and PSCA were measured in LNCaP, C4-2, and PC-3 human prostate
cancer cell lines using quantitative reverse transcriptase polymerase chain
reaction, flow cytometry, and immunohistochemistry. Of particular interest were
the differences in the expression levels of these receptors observed between
cells cultured in vitro as opposed to cell deposits grown as xenografts in
immunocompromised mice in vivo.

Membrane Receptor mRNA Expression in Cells.
The baseline mRNA expression of !", #3, NTSR1, PSMA, and PSCA, was
measured using qRT-PCR, in LNCaP, C4-2, and PC-3 human prostate cancer

!

&(!

!

cell lines; these cell types were chosen for their increasing tumorigenic potential
(20) in the order LNCaP, C4-2, and PC-3. Figure 2.1 shows growth curves for

Figure 2.1 LNCaP, C4-2, and PC-3 xenograft growth curves. Increase in
tumor volume versus days post-implantation of LNCaP, C4-2, or PC-3 cell
deposits. Circle = PC-3, Square = C4-2, and Triangle = LNCaP with n = 5, 2,
and 3 respectively.
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these three types of cell deposits grown as xenografts in the flanks of
immunocompromised mice. The growth curves suggest that the PC-3 xenografts
grow much more rapidly when implanted in the flanks of nude mice, compared to
the LNCaP and C4-2 xenografts and, therefore, the PC-3 cell line is much more
tumorigenic in this site of implantation. A summary of the mRNA expression is
given in Table 2.2, where the data are reported relative to the least tumorigenic
cell line, LNCaP.
Table 2.2 Receptor mRNA and Protein Expression in Cells and Tumors
Cell Line/
Xenograft
LNCaP
C4-2
PC-3
LNCaP
C4-2
PC-3
LNCaP
C4-2
PC-3
LNCaP
C4-2
PC-3

1

LNCaP
C4-2
PC-3

Cell mRNA
Expression

Tissue mRNA
Expression

Cell Epitope-Density

PSMA1
1.00 ± 0.09
0.51 ± 0.04
0.01 ± 0.00
PSCA1
1.00 ± 0.09
0.01 ± 0.00
1.57 ± 0.11
!" 1
1.00 ± 0.02
2.09 ± 0.18
18.61 ± 1.59
#3 1
1.00 ± 0.08
31.45 ± 2.25
5.39 ± 0.17
NTSR11
1.00 ± 0.09
2.92 ± 0.23
9.77 ± 0.73

PSMA1
1.00 ± 0.08
1.37 ± 0.11
0.01 ± 0.00
PSCA1
1.00 ± 0.07
3.81 ± 0.33
1.20 ± 0.10
!" 1
1.00 ± 0.64
3.23 ± 0.05
2.94 ± 0.20
#3 1
1.00 ± 0.05
1.21 ± 0.01
316.60 ± 26.64
NTSR11
1.00 ± 0.03
0.05 ± 0.01
88.82 ± 7.61

PSMA2
105.00 ± 10.0 (104)
167.00 ± 28.0 (104)
1.42 ± 0.48 (104)
PSCA2
0
0
0
!" # 3 2
1.12 ± 0.11 (104)
1.17 ± 0.46 (104)
0.77 ± 0.02 (104)
NA
NA
NA
NA
NTSR13
67.9 ± 27.1
79.3 ± 15.1
15.9 ± 22.4

Expression relative to LNCaP
Receptors per cell
3
Mean channel fluorescence
NA: not applicable
2
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The LNCaP cell line had the highest amount of PSMA mRNA expression
in vitro, but had lower mRNA levels for all of the other receptors, compared to the
other two cell lines.

The PC-3 cell line, which has the highest tumorigenic

potential (20) and was originally collected as a bone metastasis from a patient
with CRPC (13) was almost devoid of PSMA mRNA, but showed the highest
mRNA expression for !", NTSR1, and PSCA of all the cell lines. The PC-3 cells
also made 5-fold more of the integrin #3 mRNA than the LNCaP cells. These
findings imply that an inverse relationship may exist between the tumorigenicity
of these cell lines and their PSMA mRNA expression. Conversely, the cellular
tumorigenicity appears to positively correlate with the mRNA expression levels of
the other three membrane receptors.

The C4-2 cell line, a moderately

tumorigenic, androgen-independent progeny of LNCaP cells (13), had the
highest level of #3 integrin mRNA expression and a 2- to 3-fold greater mRNA
expression of !" and NTSR1 than that found for LNCaP cells.

Membrane Receptor mRNA Expression in Xenografts.
In order to determine if the murine microenvironment altered mRNA
expression in xenografts as compared to cells, we next measured receptor
mRNA levels in LNCaP, C4-2, and PC-3 human prostate cancer cell xenografts
grown as subcutaneous tumors in immunocompromised mice. C4-2 and LNCaP
xenografts displayed significant PSMA mRNA expression, while the PC-3
xenograft was essentially devoid of PSMA mRNA. The PC-3 xenograft, similar to
the cultured PC-3 cells, showed the highest NTSR1 mRNA expression, an ~88-
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fold increase with respect to the LNCaP xenograft. The PC-3 xenograft also had
~316-fold higher #3 mRNA expression and elevated mRNA expression of both !"
and PSCA, compared to the LNCaP xenograft.

Unexpectedly, the C4-2

xenograft had almost 4-fold higher PSCA mRNA expression, compared to the
LNCaP xenograft even though the C4-2 cells lacked PSCA mRNA expression in
vitro. Additionally, the C4-2 cell line, which expressed the highest amount of #3
expression, at a ratio of ~ 30:1 over LNCaP cells, and the second highest amount
of NTSR1 mRNA expression, in vitro, lost virtually all of its NTSR1 mRNA
expression in the xenograft and also had an ~ 50-fold reduction in #3 mRNA in
vivo.

Comparison of Membrane Receptor mRNA Expression in Cells and
Xenografts
To determine the changes in !", #3, NTSR1, PSMA, and PSCA mRNA
expression that may occur when cells grown in a semi-defined medium in vitro
are transferred to a more physiological and complex environment in vivo, the
qRT-PCR data for the membrane receptors’ mRNA expression in xenografts was
compared to each corresponding cell line. The results (Table 2.3) shows that
PSMA mRNA decreased by about 50 % in all of the xenografts compared to the
same cells grown in culture. A similar decrease in mRNA expression in vivo was
evident for PSCA in LNCaP and PC-3 xenografts. However, the C4-2 xenograft
displayed PSCA mRNA expression that markedly increased by ~1450-fold in the
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Table 2.3

Comparison of mRNA Expression Between Cells and

Xenografts
Cell Line/Xenograft

Xenograft mRNA Expression
Relative to Cells

PSMA1
LNCaP
0.30 ± 0.02
C4-2
0.63 ± 0.04
PC-3
0.55 ± 0.05
PSCA1
LNCaP
0.48 ± 0.03
C4-2
1451.15 ± 96.37
PC-3
0.37 ± 0.03
!" 1
LNCaP
1.69 ± 1.08
C4-2
2.61 ± 0.04
PC-3
0.27 ± 0.02
#3 1
LNCaP
0.42 ± 0.02
C4-2
0.02 ± 0.00
PC-3
24.79 ± 2.09
NTSR11
LNCaP
67.66 ± 2.30
C4-2
1.16 ± 0.11
PC-3
615.35 ± 20.25
1
mRNA expression relative to the corresponding cell line grown in culture
xenograft relative to C4-2 cells. The C4-2 xenograft also exhibited modest 1.2 to
2.6-fold increases in !" and NTSR1 mRNA expression relative to C4-2 cells.
Large increases in the NTSR1 (615 X) and #3 (25 X) mRNA expression were
also found in PC-3 xenografts compared to the expression in cells. These data
suggested that mRNA expression changed in different environments (in vitro
versus in vivo), and added support to the correlation mentioned above between
tumorigenicity and expression of cellular mRNA for !"#3, NTSR1, and PSCA.
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Membrane Receptor Protein Expression in Cells
It is well known that mRNA expression, as measured both in vitro and in
vivo, may not always be representative of actual protein expression levels (21).
Therefore, we measured the number of !"#3, NTSR1, PSMA, and PSCA
membrane receptors on the surface of each of the cell lines using flow cytometry
and epitope-density calibration particles (See methods). Although the LNCaP
cells were found (Table 2.2) to possess a great number (~ 1 million) of PSMA
proteins per cell, the C4-2 cells displayed the highest PSMA protein expression
with ~ 1.7 million PSMA receptors per cell. Interestingly, although the PC-3 cells
were found to contain only low, essentially background, levels of PSMA mRNA,
both in vitro and in vivo, a modest number (~14,000 per PC-3 cell) of PSMA
proteins were found on the cell surface.

Both C4-2 and LNCaP cell lines

expressed ~11,500 !"#3 integrins per cell, while the PC-3 cells showed less at
~7,700 !"#3 integrins per cell. By measuring the Mean Channel Fluorescence for
the NTSR1 protein we found that both LNCaP and C4-2 cells had high
expression of NTSR1 on the surface of the cells. The PC-3 cells had ~ 4.5-fold
less NTSR1 protein expression in vitro, compared to LNCaP and C4-2 cells,
even though the PC-3 cells had the highest NTSR1 mRNA expression in vitro.
The PSCA protein was not expressed on the surface of any of the three cell lines
in vitro.
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Immunohistochemistry for PSCA in Xenografts
Even though the PSCA protein could not be detected (Table 2.2) on the
surfaces of our cell lines, the mRNA expression data from the xenografts (Table
2.3) indicated that PSCA might be actually expressed in vivo, particularly for the
C4-2 cell line where these xenografts made more than 1400 times as much
mRNA as the cells. For this reason, PSCA protein expression was determined
by immunohistochemistry (IHC) in LNCaP, C4-2, and PC-3 xenografts generated
in immunocompromised mice. Although PSCA protein was undetectable on the
surfaces of cells cultured in vitro by the flow cytometric technique (Table 2.2),
punctate staining for PSCA was observed within the tissue cells by IHC in all
xenografts (Figure 2.2A-C). The staining intensity for PSCA in these xenografts
was comparable to the intensity found in human prostate cancer tissue used as a
positive control (Figure 2.2F), while there was a complete absence of PSCA
staining, either in the mouse splenic tissue (Figure 2.2E), or human prostate
cancer tissue incubated in the absence of the primary antibody (Figure 2.2D),
which were used as negative controls. The staining for PSCA observed in the
IHC of the xenografts was the same type of punctate staining as reported by
others in human tumors, and in LAPC-4 cells that are known to highly-express
surface PSCA (22).
Taken together, the mRNA and protein data emphasize that regulation of
mRNA expression of the membrane bound and potential target proteins !"#3,
NTSR1, PSMA, and PSCA in prostate cancer cells with different tumorigenic
potential can be influenced by factors of the microenvironment, such as in murine
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Figure 2.2

Immunohistochemical staining for PSCA in human prostate

cancer xenografts in immunocompromised mice and in human prostate
cancer tissue. (A) LNCaP xenograft; (B) C4-2 xenograft; (C) PC-3 xenograft;
(D) human malignant prostate tissue in the absence of primary antibody
[negative control]; (E) mouse spleen [negative control]; (F) human malignant
prostate tissue in the presence of primary antibody [positive control]. Scale bars
are 20 µm.
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xenotransplants. In addition, correlations appear to exist between membrane
receptor expression signatures and tumorigenicity, but mRNA expression levels
for these proteins do not translate directly to equivalent expression levels of
membrane bound protein. These trends are graphically summarized in Figure
2.3.

Discussion
Three main findings are reported in this study that are of importance for
research on improved prostate cancer imaging and therapeutic targeting agents,
as exemplified by our previously reported functionalized iron oxide nanoparticles
(23). First, our findings indicate the necessity of verifying the presence of target
proteins at the cell surface, as the level of mRNA expression does not
necessarily translate into protein expression levels.

This discrepancy was

evident for PSMA expression in PC-3 cells. We have confirmed that PC-3 cells
express little or no PSMA (24), even though these cells represent the most
tumorigenic and advanced prostate cancer cell line examined here. On the other
hand, in advanced CRPC in humans, PSMA expression increased markedly with
tumor grade, stage, and after androgen-deprivation therapy (25). Our data show
a 100-fold decrease in the expression of PSMA mRNA in PC-3 cells and
xenografts compared with the LNCaP and C4-2 lines. This decrease in mRNA
corresponded to a similar ~100-fold decrease (to ~14,000 from more than 1
million) in the number of PSMA receptors per cell (Figure 2.3A and Table 2.2).
Further discrepancies were observed for PSCA, for which even though mRNA
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Figure 2.3

Trends of membrane receptor mRNA and protein expression in

human prostate cancer cells and in murine xenografts.

Expression of

membrane receptors PSMA (A), PSCA (B), integrin !$ (C), integrin #3 (D), and
NTSR1 (E) for human prostate cancer cells of increasing tumorigenic potential, in
the order: LNCaP, C4-2, and PC-3. Messenger RNA expression levels for cells
cultured in vitro (front shapes) and as xenografts in vivo (middle shapes), and
protein levels (back shapes) are shown normalized to LNCaP cells or xenografts.
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was expressed in all of the cells analyzed, and no protein could be detected on
their cell surfaces (Figure 2.3B and Table 2.2), was yet expressed in xenografts
(Figure 2.2A-C). We found that !"#3 protein expression was comparable in all
three of the cell lines, although both !" and #3 mRNA levels appeared to increase
with tumorigenicity in the three different cell lines and xenografts. Similar trends
were observed for NTSR1 in C4-2 and PC-3 cells (Figure 2.3E), indicating that
the comparative rate of protein translation for these surface markers can greatly
differ in prostate cancer cells of various origins.
A second important finding is the discordant expression of some of the
surface markers under investigation between cells grown in culture and as
xenografts in immunocompromised mice.

Marked differences were found for

integrin #3, NTSR1, and PSCA (Figure 2.3 and Table 2.3). Most prominently,
PSCA mRNA expression was dramatically enhanced in C4-2 xenografts (Figure
2.3B and Table 2.3) but the protein was not detectable on the surface of the
parent cell line. The presence of the PSCA protein in C4-2 and other xenografts,
verified by IHC, resembled PSCA expression in human tissues (Figure 2.2).
PSCA is a glycosylphosphatidylinositol (GPI)-anchored membrane antigen that
has been reported to be over-expressed in both primary and metastatic prostate
cancer lesions (18,26,27). Since we measured PSCA mRNA expression both in
vitro and in vivo in all cell lines, one possible explanation for the lack of PSCA
protein in vitro could be that PSCA protein is not translated in the absence of the
extracellular matrix (ECM).

GPI-anchors are known to be added to the C-

terminus of peptides as a post-translational modification (28), and thus, PSCA
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may not have the proper GPI-anchor attached in vitro.

Although a detailed

understanding of PSCA regulation is still elusive, our data suggest that PSCA
expression is affected by cell type and ECM dependent contact.
Integrin !"#3 has been proposed as a neovasculature-targeting motif for
diagnostics and therapeutics due to its over-expression on newly formed
vasculature within tumors (16,29-32).

In this study, both integrin subunits

experienced an induction of expression in vivo in the more tumorigenic cell types,
i.e. C4-2 and PC-3, potentially as a consequence of cell-cell and cell-ECM
interactions. Similarly, relative strong inductions in the in vivo setting were
observed for NTSR1 in LNCaP and PC-3 cells (Figure 2.3E and Table 2.3). The
NTSR1 receptor is over-expressed in numerous types of solid tumors and
NTSR1 receptor binding to neurotensin (NT) has been reported to increase
proliferation of several types of cancer cells, including prostate cancer cells
(17,33). Further, NT functions via autocrine, paracrine, and endocrine actions in
prostate cancer tissues (34,35). Consequently, a plausible explanation for the
observed induction of NTSR1 in xenografts could be due to autocrine NT
stimulation.
A final important finding is that a relationship appears to exist between
membrane receptor signatures and tumorigenicity. We found that PSMA mRNA
and protein expression levels tended to be inversely related to tumorigenic
potential, both in vitro and in vivo. Additionally, !"#3 tended to increase with
tumorigenic potential both in vitro and in vivo (Figure 2.3C-D). It is possible that
the degree of !"#3 expression is not only dependent on the extent of
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vascularization within tumors, but also on the tumorigenic potential of the cells.
We also found that NTSR1 mRNA expression increased with increasing
tumorigenic potential both in vitro and in vivo yet, NTSR1 protein expression was
inversely related to tumorigenic potential in vitro, reflecting our first main finding
above. In the future, it may also be worthwhile to compare membrane receptor
expression changes that may or may not occur when the cell deposits are
instead implanted in the prostate or bone of immunocompromised mice.
Taken together, our data demonstrate that the membrane receptor
expression profiles are altered with analogous changes in tumorigenic potential
and that these alterations may comprise signatures of the tumorigenic state.
Moreover, these membrane receptor signatures were altered for in vitro and in
vivo models.

We conclude that targeting nanoparticles, diagnostics, and

therapeutics with multiple antibodies or peptides against PSMA as well as !"#3,
NTSR1, and/or PSCA may be more beneficial in diagnosing and treating early
stage prostate cancer and CRPC than PSMA targeting alone. In addition, a
major finding is that cell lines that do not express certain receptors, such as
PSCA, in vitro, may very well express these receptors in vivo and prove to be
useful receptors for targeting novel agents in humans.

Conclusions
PSMA is the membrane receptor most frequently used for targeting
prostate cancer cells (23,30,36-38), and we conclude that LNCaP and the
castration resistant and more tumorigenic C4-2 cells are ideal cell models for
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PSMA directed targeting, as these cell lines display relatively high and persistent
PSMA protein expression in vitro and in vivo. However, we provide evidence that
additional targeting motifs exist that could increase the specificity and efficacy of
imaging and treatment schemes, as shown by the expression of !"#3, NTSR1,
and PSCA in relevant cell and xenograft models of prostate cancer. In fact, cotargeting strategies may be necessary in light of the fact that membrane receptor
signatures may change over time as the tumor progresses and that intra-tumoral
heterogeneity may lead to variability in expression of any single membrane
receptor, thereby hampering efficacy.

Furthermore, we found that membrane

receptor signatures change not only with alterations in tumorigenicity but are also
modified in in vitro and in vivo models. We suggest that designing targeted
diagnostics and/or therapeutics using cell models such as LNCaP, C4-2, and PC3 should ideally include up-front in vivo measurements of the target membrane
receptors, which may reveal optimal models under physiologically relevant
conditions.
This study provides a novel comparison of expression signatures of
prominent membrane receptors for prostate cancer targeting using widely used
prostate cancer cells grown in vitro and in vivo.

Knowledge reported herein

should be helpful in guiding the development of targeting strategies for imaging
and therapeutic agents using membrane receptor signatures rather than single
membrane-bound targets. This approach should in turn overcome the difficulties
often encountered when translating in vitro applications to pre-clinical models
and when transitioning such applications towards clinical use.
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Abstract
We report the synthesis, from simple salts, and the physical characterization of
superparamagnetic iron platinum nanoparticles (SIPPs) suitable for use as
contrast agents in magnetic resonance imaging.

The properties of these

particles were determined by means of transmission electron microscopy (TEM),
thermogravimetric analysis (TGA), inductively coupled plasma-optical emission
spectroscopy (ICP-OES), superconducting quantum interference device (SQUID)
magnetometry, and nuclear magnetic resonance (NMR) relaxivity at 4.7 Tesla.
TEM showed that the diameters of the particles ranged from 9.3 nm to 10 nm,
depending on the mole ratio of iron to platinum precursors, and on the
concentration of Octadecylamine (ODA) used in their preparation. The iron to
platinum stoichiometry determined by ICP-OES varied from 1.4:1 to 3.7:1 and
was similarly dependant on the initial mole ratios of iron and platinum salts, as
well as on the concentration of ODA in the reaction.

SQUID magnetometry

showed that the SIPPs were superparamagnetic and had magnetic moments that
increased with increasing iron content from 62 to 72 A m2/kg Fe. The measured
relaxivities of the SIPPs at 4.7 Tesla were higher than commercially available
superparamagnetic iron oxide nanoparticles (SPIONs), suggesting that these
particles may be superior contrast agents in T2-weighted magnetic resonance
imaging (MRI).
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Introduction
Ferromagnetic

face-centered

tetragonal

(fct)

iron

platinum

(FePt)

nanoparticles have frequently been synthesized, for use in magnetic storage
devices, by annealing superparamagnetic iron platinum particles (SIPPs) at
elevated temperatures (1-7). The precursor SIPPs have also found a niche as
contrast agents in magnetic resonance imaging (MRI) (8-10). Magnetic
nanoparticles that cause larger perturbations in the relaxation times of water
molecules in close proximity to the particles typically have higher magnetic
moments and SIPPs have been reported to have extremely high volume
magnetizations between 6 x 105 A/m and 1 x 106 A/m (10-13). These high
volume magnetizations suggest that SIPP syntheses could be optimized to be
superior MRI contrast agents. Once developed, biocompatible SIPP contrast
agents will also need to go through animal toxicity studies, as this information is
not currently available.
Iron pentacarbonyl, Fe(CO)5, is a hazardous reagent that is frequently
used in the synthesis of magnetic nanoparticles (4,6,14). We have previously
described, along with others, a synthesis method to produce SIPPs that are ~ 9
nm in diameter using simple iron and platinum salts and the ligand
Octadecylamine (ODA) as the stabilizing ligand (10,11). This synthesis tends to
be a safer and environmentally friendlier method, as it uses less toxic reagents
and ODA acts as both the solvent and the ligand, thus reducing the number of
reagents needed.

Here, we describe the synthesis of SIPPs using different

concentrations of the salt precursors and ODA and show that the sizes and
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magnetic moments of these particles can be tailored by controlling both the initial
mole ratios of the precursor metal salts and the concentration of ODA in the
reaction mixture. The SIPPs described here were also refluxed for a shorter
duration of time (30 minutes) and heated to a higher temperature (340 °C) than
previously reported (10). Furthermore, we describe the physical and magnetic
characterization of the nanoparticles resulting from these various syntheses and
show that SIPPs are superior T2-weighted contrast agents for MRI, when
compared to superparamagnetic iron oxide nanoparticles (SPIONs).

Experimental

Materials
Iron

nitrate

nonahydrate

(Fe(NO3)3·9H2O),

Platinum

(II)

acetylacetonate

(Pt(Acac)2), and 1-Octadecylamine (ODA) were purchased from Fisher Scientific
(Pittsburgh, PA). Nonylphenoxy propenyl polyethylate alcohol (RN-10) was a
generous gift from Dai-Ichi Kogyo Seiyaku (Kyoto, Japan).

The temperature

controller (model 210-J) was purchased from J-KEM Scientific, INC (St. Louis,
MO). Heating mantles were purchased from Glas-Col, LLC (Terre Haute, IN)
and

glassware

was

purchased

from

Quark

Glass

(Vineland,

NJ).

Superparamagnetic iron oxide nanoparticles (SPIONs) were purchased from
Miltenyi Biotec as their µMAC product. All other chemicals and supplies were
purchased from common manufacturers.
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SIPP Synthesis
Nanoparticles were synthesized using a modification of a procedure due to
Taylor et al. (10) and Zhao et al. (11). For SIPP#1, 1.0 mmol Fe(NO3)3·9H2O and
1.0 mmol Pt(Acac)2 were added to 12.5 mmol ODA in a 25 mL 3 neck round
bottom flask fitted with a reflux condenser. After the apparatus was assembled,
the reaction was heated to 340 °C at a rate of 200 °C/hr. Refluxing at 340 °C
was continued for 30 minutes at which point the reaction was removed from the
heat and allowed to cool to room temperature. The resulting black particles were
collected in hexane and subjected to repeated ethanol washes with
centrifugation. SIPP#2 and SIPP#3 were prepared in the same manner as
SIPP#1 except 1.0 mmol Fe(NO3)3·9H2O and 1.0 mmol Pt(Acac)2 were added to
25.0 mmol ODA for SIPP#2, while 2.0 mmol Fe(NO3)3·9H2O and 1.0 mmol
Pt(Acac)2 were added to 12.5 mmol ODA for SIPP#3.

The SIPPs were

resuspended in hexane and stored at room temperature. A typical synthesis as
described above produced ~20 mg of SIPPs.

Physical Characterization of SIPPs
Transmission electron microscopy (TEM) was used to determine the size and
polydispersity of the particle populations. A drop of the hexane suspension of the
SIPPs was applied to carbon-coated grids. After the solvent evaporated, the
samples were imaged on a Hitachi 7500 transmission electron microscope with
an acceleration voltage of 80 kV.

Particle diameters were calculated using

ImageJ Software (15). At least 1000 particles were counted and the mean Feret
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diameters and standard deviations were calculated. The compositions of the
SIPPs were investigated with thermogravimetric analysis (TGA).

Aliquots of

SIPPs were evaporated in TGA sample cups (Robocasting Enterprises LLC,
Albuquerque, NM) and allowed to evaporate.

Weight loss profiles were

measured with a SDT Q600 TGA/DSC (TA Instruments, New Castle, Delaware)
under nitrogen flow. The ODA and FePt content were determined by measuring
the mass change while the temperature was raised from room temperature to
1000 °C at a 20 °C/min heating rate. Inductively coupled plasma-optical emission
spectroscopy (ICP-OES) was used to measure the metal content and iron to
platinum stoichiometry of each synthesis. Prior to analysis, gentle refluxing with
nitric and hydrochloric acids digested aliquots of SIPPs.

After cooling, the

samples were made up to volume, mixed and centrifuged. Samples were then
analyzed

using

a

PerkinElmer

Optima

5300DV

ICP-OES

using

the

recommended wavelengths for each of the analytes. Analysis was performed in
an axial mode to improve detection limits.

A blank and set of calibration

standards were used to establish a three-point calibration curve.

Calibration

verification samples (ICBV and ICV) were analyzed prior to analyzing the
samples. Analyte peaks were examined and peak locations and background
points were adjusted for optimum recoveries.

Magnetic Characterization of SIPPs
Superconducting quantum interference device (SQUID) magnetometry was used
to measure the blocking temperatures and saturation magnetizations of the
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SIPPs.

Aliquots (100 %L) of the hexane suspension of SIPPs were placed in 5

mm, economy 8-inch NMR tubes (Wilmad LabGlass, Vinelanad NJ, USA) and
allowed to evaporate overnight.

Magnetic measurements were made on a

Quantum Design MPMS-7 SQUID magnetometer.

Temperature sweeps

between 0 and 400 K were performed by zero-field cooling the sample and then
measuring the magnetic moment as a function of temperature under the
influence of a weak magnetic field (1 mT) during warming and subsequent
cooling. This procedure yields both a zero-field-cooled (ZFC) and field-cooled
(FC) curve, respectively. Values of the blocking temperature (TB) were recorded
by determining the peak location in each ZFC curve.

Saturation magnetizations

were measured at human body temperature (310 K) by varying the applied field
from -5 to 5 Tesla. Mass magnetizations were calculated with the known iron
concentrations determined with ICP-OES. The iron to platinum ratio, determined
with ICP-OES, was used to calculate the density of an fcc unit cell representing
the naked SIPPs without ODA ligand.

The weight percent of ODA on the

particles, measured with TGA, was used with the density calculated for naked
SIPPs to estimate the density of ODA coated SIPPs. Volume magnetizations
were calculated using this calculated density for ODA coated SIPPs.

Magnetic Resonance Imaging and Relaxivities
Increasing concentrations of SIPPs (0.02 to 0.3 mM iron) or SPIONs (0.1 to 0.62
mM iron) were added to 1% agarose in 2.0 mL self-standing micro-centrifuge
tubes (Corning, Corning, NY). Samples were imaged on a 4.7 Tesla Bruker
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Biospin (Billerica, MA) MRI system with Paravision 4.0 software. Samples were
imaged with a 512 x 256 matrix, a variable TE, and TR = 10 sec.

T1

measurements were acquired by inversion-recovery with 15 interpulse delays.
Spin- and gradient echo sequences were used to measure T2, and T2*,
respectively. The MRI samples were then digested as above for ICP-OES and
the iron concentration was determined. The relaxation rates, Rn, (= 1/Tn) were
calculated and plotted versus the ICP-OES-determined iron concentration of
each sample. Linear regression was used to fit the data and the relaxivity (rn) of
each SIPP synthesis is given as the slope of the resulting line in units of Hz/mM
Fe.

Results and Discussion
SIPPs were synthesized using two different mole ratios of iron to platinum
precursors, and with two different amounts of ODA.

Table 3.1 outlines the

general synthetic parameters used for each of the three SIPP syntheses that we
report. We began by producing SIPPs using a 1:1 mole ratio of the metal salt
precursors and 12.5 mmol of ODA (SIPP#1).

Table 3.1 The parameters used in the synthesis of SIPPs.
Sample
Molar Ratioa
SIPP#1
1
SIPP#2
1
SIPP#3
2
a
Molar ratio of Fe(NO3)3 9H2O:Pt(Acac)2
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ODA (mmol)
12.5
25.0
12.5

!

Since iron provides the magnetism for these nanoparticles, we expected that
increasing the amount of iron precursor would generate SIPPs with a greater
Fe:Pt mole ratio and thus a higher magnetic moment. For this reason, we also
synthesized SIPPs with a 2:1 mole ratio of iron to platinum, while keeping the
amount of ODA at 12.5 mmol (SIPP#3).

Additionally, we expected that the

amount of ODA in the reaction mixture would effect the formation and final
characteristics of the SIPPs. To explore this possibility, we synthesized SIPPs
with a 1:1 molar ratio of iron to platinum and increased the amount of ODA to
25.0 mmol (SIPP#2). TEM images of particles from each SIPP synthesis are
shown in Figure 3.1. From the TEM images, it is seen that the nanoparticles are
roughly spherical in shape. Using ImageJ software9 to analyze the TEM images,
we found that the SIPPs had average diameters that ranged from 9.3 ± 1.9 nm
(SIPP#1) to 10 ± 3.4 nm (SIPP#3). This finding suggested that as the mole ratio
of iron added to the reaction was increased, the size of the particles increased
slightly. In addition, the size of the particles also increased as the concentration
of ODA was increased in the reaction.

To understand these trends, we used

ICP-OES to determine the composition of the SIPPs and found that the iron to
platinum stoichiometry increased with increasing iron precursor and ODA. Also
of note, is that the polydispersity of the SIPPs increased with increasing size and
Fe:Pt stoichiometry, as was evident by the increase in the standard deviation in
the diameter describing the size distribution of the particles.

Table 3.2

summarizes the physical and magnetic characteristics of the three SIPP
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Figure 3.1
microscopy.

Images of SIPPs acquired using transmission electron
Drops of SIPPs were applied to carbon-coated grids and the

samples were imaged at an acceleration voltage of 80 kV.
SIPP#2, (C) SIPP#3. Scale bars = 20 nm.
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(A) SIPP#1, (B)
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Table 3.2 Physical and magnetic characteristics of SIPPs and SPIONs.
Variable

Units

SIPP#1

SIPP#2

SIPP#3

SPIONsa

R

Fe:Pt ratio

---

1.44

2.35

3.67

---

D

Diameter of
particle

nm

9.28

9.98

10.03

50b

&

Standard
deviation in
diameter

nm

1.94

2.90

3.43

---

'

Density

g/cm3

5.2

5.2

5.2

2.5c

M

Mass of iron
per particle

pg

1.5 x 10-6

2.2 x 10-6

2.6 x 10-6

1.6 x 10-5

Fe
concentration
of solution

g/mL

1.2 x 10-3

1.9 x 10-3

2.8 x 10-2

2.7 x 10-4 c

Cp

Particle
concentration

Particle
s/mL

8 x 1014

9 x 1014

1 x 1016

2 x 1014 c

Tb

Blocking
temperature

Kelvin

170

210

195

155c

K

Effective
anisotropy
energy

J/m3

1.4 x 105

1.4 x 105

1.3 x 105

µM

Mass
magnetization

A m2/kg
Fe

61.7

69.2

71.8

82.0c

µV

Volume
magnetization

A/m

7.4 x 105

7.4 x 105

6.8 x 105

2.0 x 105

CF
e

a

MACS® iron oxide particles from Miltenyi Biotec
Hydrodynamic diameter according to manufacturer
c
Taylor et al. (10)
d
Calculated using a magnetic core diameter of 10 nm
b
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1.2 x 105
c,d
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syntheses, compared with commercially available SPIONs.

It is clear that the

amount of ODA plays an important role in the formation of the FePt alloy and the
resultant iron to platinum stoichiometry. Zhao et al. (11) previously suggested
that an excess of ODA was needed in this particular synthetic method and that
the initial decomposition of the iron and platinum salts led to three possible
products; pure iron, iron oxides, or FePt nanoparticles. The excess ODA is
thought to react with the iron oxides, forming an intermediate, Fe(ODA)3 complex
(11). The catalytic activity of the FePt nanoparticles then provides a pathway
available to the pure iron. It appears that by increasing the amount of ODA to
25.0 mmol, twice the amount previously used (10,11), that more iron is deposited
into the FePt alloy.
To further investigate the composition of the SIPPs, TGA was used to
remove the organic layer on the particles and determine the weight percents of
ODA and naked FePt. The TGA data for SIPP#1 is shown in Figure 3.2. ODA
has a boiling point around 347 °C and, therefore, we suggest that the
pronounced weight loss seen from ~ 300 to 400 °C is due to the removal of ODA
from the SIPP surface. It is plausible that some of this weight loss could also be
due to iron oxides in the samples. The thermal decomposition of naked SPIONs
has been reported to occur from 300 to 400 °C (16). This overlap in the thermal
decomposition temperatures of the ODA and iron oxides make it difficult to
determine from the TGA data what percentage of the weight loss may or may not
be due to iron oxide contaminants in the SIPPs. The TGA results suggest that
the organic layer comprised approximately 20% of the particle mass, much less
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Figure 3.2

Weight loss and heat flow curves for SIPP#1. Dried SIPPs were

added to TGA sample cups and heated at 20 °C/hr from room temperature to
1000 °C.

The weight percent of organic coating and naked FePt was then

extrapolated.

The curve labeled with arrows shows the decrease in weight

percent while the unlabeled curve shows the heat flow.
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than previously reported with lower temperature preparations that used increased
reaction times (10,11). All of the syntheses showed similar decomposition curves
and indicated that the SIPPS were between 18% and 22% ODA by mass.
We expected that increasing the concentration of iron per SIPP by
increasing the mole ratio of iron to platinum in the reaction mixture would lead to
a higher magnetic moment simply due to the larger amount of magnetic iron that
would be present in each particle.

We therefore determined the magnetic

characteristics of the various SIPP syntheses using SQUID magnetometry.
Figure 3.3 shows the mass magnetization as a function of the applied magnetic
field for the three SIPP syntheses. In agreement with our expectations, both the
mass magnetization and the volume magnetization increased with increasing iron
content from SIPP#1 to SIPP#2. Once the iron to platinum ratio increased above
3.5, though, the volume magnetization began to decrease, while the mass
magnetization continued to increase. We calculated the anisotropy of each SIPP
synthesis

based

on

the

blocking

temperature

measured

by

SQUID

magnetometry. The relationship between the anisotropy and the blocking
temperature (K) is
(1)
where k is Boltzmann’s constant, TB is the blocking temperature of the individual
SIPP synthesis, and V is the volume of a single particle in units of cm3. The
constant 25 is calculated using a relaxation time of 1 x 10-9 seconds and a
measurement time of 100 seconds.

Table 3.2 shows that the anisotropy

remained fairly constant for all of the SIPP syntheses. This did not support the
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Figure 3.3

Mass magnetization of SIPPs measured using SQUID and ICP.

100 µL aliquots of SIPPs were evaporated in constricted NMR tubes and sealed.
SQUID magnetometry data was collected at 310 Kelvin from -5 to 5 Tesla. Also,
100 µL aliquots of SIPPs were added to conical tubes and analyzed with ICP to
determine the mass of iron in each SQUID sample. The solid line is for SIPP#1,
the long dashed line is for SIPP#2, and the dotted line is for SIPP#3.
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idea that magnetic order increases with iron content. The effective anisotropy
constants of the synthesized nanoparticles are in good agreement with
magnetocrystalline anisotropy constants for SIPPs previously reported (8,17).
Further studies using high-resolution TEM and X-ray diffraction methods may be
able to increase our understanding of any crystalline differences in the SIPPs
synthesized.
Finally, to test whether the SIPPs could be beneficial as MRI contrast agents, we
chose to examine SIPP#2, since it had intermediate stoichiometry, size, and
magnetic properties compared to the other SIPPs. Relaxivities were measured
at 4.7 Tesla for SIPP#2 and compared with relaxivities of ~50 nm %MACs®
(Miltenyi Biotec, Carlsbad, CA) SPIONs, also measured at 4.7 Tesla. We first
imaged the %MAC particles using TEM and measured their magnetization using
SQUID magnetometry.(10) Figure 3.4 shows a representative TEM image of the
%MACs SPIONs showing a mean magnetic core diameter of ~20 nm, although
the hydrodynamic diameters may be larger due to the fact that coatings on the
particles are not visible using TEM.

The manufacturer suggests that these

dextran-coated SPIONs are 50 nm in diameter but that the magnetic cores are ~
10 nm. This suggests that although the hydrodynamic diameter is larger for the
SPIONs compared to the SIPPs, the magnetic cores are similar in size and,
therefore, the SIPP and SPION magnetic properties can be compared. Table 3.2
summarizes our characterizations of the %MAC particles using TEM, SQUID, and
ICP-OES. It is clear that the volume magnetization of the SPIONs is ~ 3.5 fold
less than determined for our SIPPs. Next, we prepared %MAC relaxivity samples
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Figure 3.4

Image of $MAC SPIONs acquired using transmission electron

microscopy. A drop of %MAC SPIONs was applied to a carbon-coated grid.
The sample was imaged at an acceleration voltage of 80 kV. Scale bar = 50 nm.
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by adding increasing amounts of SPIONs to 1 % agarose (10). We also prepared
SIPP#2 relaxivity samples by first magnetically separating the SIPPs and then
suspending the particles in the initial volume of a strong surfactant, RN-10, to
disperse the hydrophobic SIPPs in the aqueous agarose. Increasing amounts of
the RN-10 stabilized SIPPs were then added to 1 % agarose in plastic sample
tubes. Table 3.3 shows the relaxivities measured at 4.7 Tesla, while Figure 3.5
shows the longitudinal and transverse relaxation rates of the SIPPs and SPIONs
as a function of iron concentration. It is apparent that the SIPPs have a 3 fold
Table 3.3 SIPP and SPION relaxivities measured at 4.7 Tesla
Variable
Unit
SPIONa
SIPP#2
r1
Hz/mM Fe
1.67b
1.18
b
r2
Hz/mM Fe
21.37
62.2
r2 *
Hz/mM Fe
436b
253
b
r2/r1
--13
53
a
MACS® iron oxide particles from Miltenyi Biotec
b
Taylor et al.(10)
higher r2 than the %MAC SPIONs and more than a 4-fold increase in the r2/r1
ratio. The higher measured r2/r1 ratio would be favorable for a T2-lowering MRI
contrast agent. The SIPP#2 sample had a lower mass magnetization compared
with the %MAC SPIONs, yet a much larger volume magnetization of
approximately 7.4 x 105 A/m. This volume magnetization is in good agreement
with previously reported volume magnetizations of SIPPs (between 6 x 105 A/m
and 1 x 106 A/m) (11-13). Our result is novel, though, in that we have used safer
methods, less reagents, and different temperatures to synthesize the particles for
an MRI application. This difference in the volume magnetizations for the SPIONs
and SIPPs may be due to the fact that the SPIONs are encapsulated in dextran
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Figure 3.5

A comparison of SIPP and SPION relaxivities measured at 4.7

Tesla. Increasing concentrations of particles were added to 1% agarose and
scanned at 4.7 Tesla with TR = 10 sec and TE = 40 ms. R1 and R2 values were
calculated by taking the inverse of the T1 and T2 relaxation times. The relaxation
rates (R1 and R2) were then plotted versus the iron concentration (mM Fe),
measured using ICP-OES. The slope of the linear regression is the relaxivity of
the specific particle at 4.7 Tesla. Squares = SPIONs and Circles = SIPPs. (A)
longitudinal relaxation rates (B) transverse relaxation rates.

!

*&!

!

and the SIPPs are stabilized with the strong surfactant, RN-10. It is possible that
the dextran coating decreases the relaxivities of the particles by preventing the
necessary close approach of water molecules. A current focus in our lab is to
encapsulate the SIPPs in phospholipids and again measure the relaxivities of
these particles compared with SPIONs (10). Overall, our data suggest that SIPPs
can be tailored to optimize size and magnetic properties. In addition, SIPPs may
be superior contrast agents in T2-weighted imaging when compared to SPIONs.

Summary and Conclusions
Synthesis of SIPPs, from low-toxicity precursors, was performed producing
spherical particles in the range of 9.3 nm to 10 nm. The synthesized SIPPs
showed increasing size and increasing iron to platinum stoichiometry when the
molar concentration of iron precursor increased and when the amount of ODA
was increased. The TGA results suggested that the particles were 80% naked
FePt and 20% organic ligand, by mass. The saturation magnetization of the
particles increased with increasing iron concentration, as measured with SQUID
magnetometry. Further studies are needed to elucidate the mechanism of initial
FePt nucleation and the crystalline and stability changes as the Fe to Pt
stoichiometry is increased. The synthesized SIPPs showed increased r2 and r2/r1
when compared with SPIONs, suggesting that SIPPs may be superior contrast
agents for T2-weighted MRI. Only limited cytotoxicity studies have been reported
for SIPPs and have focused on non-encapsulated SIPPs (18). Silica
encapsulated SIPPs have also been reported (19) but, to our knowledge, the
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cytotoxicity of encapsulated SIPPs has not been established. Determining the
cytotoxicity of encapsulated SIPPs would be an important future endeavor.
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Abstract
Superparamagnetic iron oxide nanoparticles (SPIONs) are the most common
type of contrast agents used in contrast agent-enhanced magnetic resonance
imaging (MRI).

Still, there is a great deal of room for improvement, and

nanoparticles with increased MRI relaxivities are needed in order to increase the
contrast enhancement in MRI applied to various medical conditions including
cancer.

We

nanoparticles

report

the

(SIPPs)

synthesis

and

of

subsequent

superparamagnetic
encapsulation

iron

using

platinum
PEGylated

phospholipids to create stealth immunomicelles (DSPE-SIPPs) that can be
specifically targeted to human prostate cancer cell lines and detected using both
MRI and fluorescence imaging. SIPP cores and DSPE-SIPPs were 8.5 nm ± 1.6
nm and 42.9 nm ± 8.2 nm in diameter and the SIPPs had a magnetic moment of
120 A m2/kg iron.

J591, a monoclonal antibody against prostate specific

membrane antigen (PSMA), was conjugated to the DSPE-SIPPs (J591-DSPESIPPs) and specific targeting of J591-DSPE-SIPPs to PSMA-expressing human
prostate cancer cell lines was demonstrated using fluorescence confocal
microscopy.

The transverse relaxivity of the DSPE-SIPPs, measured at 4.7

Tesla, was 300.6 ± 8.5 s-1 mM-1, which is 13-fold better than commercially
available SPIONs (23.8 ± 6.9 s-1 mM-1) and ~ 3-fold better than reported
relaxivities for Feridex® and Resovist®.

Our data suggest that J591-DSPE-

SIPPs specifically target human prostate cancer cells in vitro, are superior
contrast agents in T2-weighted MRI, and can be detected using fluorescence
imaging.

!

To our knowledge, this is the first report on the synthesis of
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multifunctional SIPP micelles and using SIPPs for the specific detection of
prostate cancer.

Introduction
In the United States, prostate cancer is the second most common
reason for cancer death in men (1). Accurate detection methods are important for
all aspects of the clinical management of prostate cancer, including diagnosis,
risk assessment, staging, and prognosis.

Such methods will result in

individualized and efficacious treatments for patients at risk for prostate cancer or
for its progression. Many of these tasks are currently managed by determination
of the serum biomarker prostate specific antigen (PSA). For example, serum
PSA levels are used to evaluate prostate cancer risk and progression, and justify
confirmatory biopsies to diagnose the presence of malignancy.

However,

biopsies have inherent risks such as bleeding and infection (2), and cancer is not
detected (false negative cases) in 30-50% of biopsies in patients with
subsequently confirmed malignancy due to small and inconspicuous lesions (3).
Another major issue is that ~25% - 40% of patients are over diagnosed using
current detection methods leading to superfluous biopsies (2). These findings
indicate that detection and staging of prostate cancer needs to be improved.
Novel magnetic resonance molecular imaging methods promise to markedly
increase the specificity of prostate tumor detection (4).
Our goal is to develop targeted magnetic resonance imaging (MRI) agents
for the specific detection of prostate cancer. A unifying theme in the development

!

*-!

!

of novel imaging and therapeutic modalities in recent years has been specifically
targeting these agents to cells of interest (5). The targeting motifs are often
antibodies against antigens expressed on cancerous cells but not healthy cells.
The most promising target antigen expressed specifically on prostate cancer
cells is prostate specific membrane antigen (PSMA), which is most strongly
expressed in the prostate and expression has been found to increase as tumor
grade and stage increases (6).

Additionally, many nonprostatic tumors have

been found to express PSMA in the neovasculature, but expression in healthy
vasculature has not been reported (7,8), suggesting that PSMA may also be a
general tumor antigen that could be used to detect numerous types of solid
tumors. Thus, antibodies against PSMA are an appealing choice for use as
targeting motifs for prostate cancer.
Superparamagnetic iron oxide nanoparticles (SPIONs) are the most
common type of contrast agents used in contrast agent-enhanced MRI (9).
Although SPIONs cause negative contrast in the MR images, the signal
enhancement is still lower than other common imaging techniques (10).
Therefore, novel nanoparticles with increased MRI relaxivities are needed in
order to increase the signal enhancement in MRI and the detection of cancer,
using lower doses of the contrast agents. Iron platinum (FePt) particles have
been the focus of intense research in recent years due to their high magnetic
anisotropy and high stability (11-15). Much of the interest in FePt has been
placed on producing ferromagnetic face-centered tetragonal (fct) FePt particles,
for use in magnetic storage devices, by annealing superparamagnetic face-
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centered cubic (fcc) nanoparticles at temperatures exceeding 500 °C (15-18).
However, fcc superparamagnetic iron platinum particles (SIPPs) are of interest
by themselves due to their possible use as contrast agents in MRI (19-21). For
superparamagnetic MRI contrast agents, it is thought that a higher magnetic
moment at a given magnetic field causes larger perturbations in the magnetic
relaxation times of nearby water protons and, thus, higher moment particles
should generate increased image contrast. SIPPs have previously been reported
with volume magnetizations greater than 590 emu/cm3 (6 x 105 A/m), with some
preparations approaching 1,140 emu/cm3 (1 x 106 A/m), the saturation
magnetization of bulk FePt (22-25). These reported high magnetic moments
suggested that SIPPs would be superior MRI contrast agents.
One obvious drawback to the synthesis of various types of nanoparticles
is that toxic precursors are generally used to produce the particles (14,15,26).
Often, iron pentacarbonyl, Fe(CO)5, a very hazardous reagent (27), is used as
the iron precursor in FePt syntheses (15). A number of different FePt syntheses
are described by Sun (14). Recently, Zhao et al. (23) described a method for
producing ~11 nm SIPPs using the hydrophobic surface ligand 1-Octadecylamine
(ODA) along with iron and platinum salts that are much less hazardous than
Fe(CO)5. We report the synthesis of SIPP cores using modifications of this less
hazardous method. In order to use hydrophobic core nanoparticles in vivo, the
particles must first be made biocompatible.

A plethora of methods for

encapsulating drugs and hydrophobic imaging agents, to instill biocompatibility,
have been reported and include encapsulation using hydrophilic or amphiphilic
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components such as monomers and phospholipids (28).

Additionally,

polyethylene glycol (PEG) groups on nanoparticles have been shown to increase
solubility and circulation times and decrease immunogenicity (28,29).

This

decrease in immunogenicity imparts the nanoparticles with stealth capability in
vivo.

Furthermore, biocompatible contrast agents that also incorporate a

fluorescent component offer the advantage of in vivo and ex vivo imaging using
small animal fluorescence imagers and/or fluorescence microscopy for in vivo
biodistribution studies and in vitro binding assays.

Here, we describe the

physical and magnetic characterization of SIPP cores encapsulated with a
mixture

of

[amino(polyethylene

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-Nglycol)-2000]

(DSPE-PEG),

DSPE-PEG

with

biotin

conjugated to the head group (biotin-DSPE-PEG), 1,2-dimyristoyl-sn-glycero-3phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (Liss-Rhod), and
subsequent conjugation to a monoclonal antibody (J591) against PSMA (J591DSPE-SIPPs). We also demonstrate the specific binding of J591-DSPE-SIPPs
to PSMA-positive prostate cancer cells using confocal microscopy and measure
the MR relaxivities of the DSPE-SIPPs at 4.7 Tesla. Compared to commercially
available and clinically used SPIONs, the J591-DSPE-SIPPs are superior
contrast agents in T2-weighted MRI, specifically target PSMA-positive human
prostate cancer cells, and can be detected with fluorescence microscopy. To our
knowledge, this is the first report on the synthesis of multifunctional SIPP
micelles and the first report of using SIPPs for the specific detection of prostate
cancer cells.
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Experimental Details

Materials
Iron

nitrate

nonahydrate

(Fe(NO3)3·9H2O),

Platinum

(II)

acetylacetonate

(Pt(Acac)2), and ODA were purchased from Fisher Scientific (Pittsburgh, PA).
Temperature controller (model 210-J) was purchased from J-KEM Scientific, INC
(St. Louis, MO).

Heating mantle was purchased from Glas-Col, LLC (Terre

Haute, IN) and glassware was purchased from Quark Glass (Vineland, NJ). The
phospholipids

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-

[amino(polyethylene

glycol)-2000]

(DSPE-PEG),

DSPE-PEG

with

biotin

conjugated to the head group (biotin-DSPE-PEG), and 1,2-dimyristoyl-snglycero-3-phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (Liss-Rhod)
were purchased from Avanti Polar Lipids (Alabaster, AL).

SPIONs were

purchased from Miltenyi Biotec (Carlsbad, CA) as their MACS® Streptavidin
MicroBeads product. RPMI cell culture media, fetal bovine serum, and PenicillinStreptomycin Solution were purchased from Sigma (St. Louis, MO). All other
chemicals and supplies were purchased from common manufacturers.

Synthesis of SIPP Cores
Nanoparticles were synthesized using a modification of a procedure due to Zhao
et al. (23). Briefly, 1.0 mmol Fe(NO3)3·9H2O and 1.0 mmol Pt(Acac)2 were added
to 12.5 mmol ODA in a 25 mL 3-neck round bottom flask fitted with a reflux
condenser.

!

The reaction was heated to 330 °C (200 °C/hr) with 10 °C
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recirculated cooling in the reflux condenser.

Refluxing was continued for 45

minutes at which point the reaction was removed from the heat and allowed to
cool to room temperature. The resulting black particles were collected in hexane
and subjected to repeated washing by collecting particles in conical tubes with an
external magnet, removing the supernatant, and resuspending in hexane.

Encapsulation of SIPP Cores
Phospholipid-encapsulated SIPP cores (DSPE-SIPPs) were prepared using a
thin film method. 1.5 mL of SIPP cores (1.4% solids) in hexane was added to a
20.0 mL glass scintillation vial.

A chloroform mixture of (56:1:1 mole ratio)

DSPE-PEG, biotin-DSPE-PEG, and Liss-Rhod was then added to the SIPP
cores.

The mixture was further diluted in 1.5 mL of hexane and vortexed

thoroughly. The vial was wrapped in aluminum foil and allowed to evaporate in
the dark in a chemical fume hood overnight to produce a thin film. 5.0 mL of
double-distilled water was heated to 67 °C and added to the thin film. Hydration
of the thin film was then continued in a 67 °C water bath for 1.0 hour with
vortexing every 15 minutes to produce liposomes containing SIPP cores. The
liposomes were then extruded at 67 °C through an 80 nm nuclepore track-etch
membrane filter using a mini-extruder (Avanti Polar Lipids, Alabaster, AL) to
produce ~ 45 nm DSPE-SIPP micelles. The DSPE-SIPPs were then purified
from SIPP-free micelles and excess phospholipids by collecting the magnetic
particles using an LS magnetic column placed in a VarioMACSTM magnetic
separator (Miltenyi Biotec, Carlsbad, CA). After the non-magnetic material had
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passed through the column, 8.0 mL of double-distilled water was added to the
top of the column to wash the particles. The washing was then repeated a
second time. The column was removed from the magnet and placed in a tube
rack with a 2.0 mL glass vial placed underneath the column. 2.0 mL of either
double-distilled water or phosphate buffered saline (PBS), pH 7.4, was used to
elute the purified DSPE-SIPPs from the column.

Physical Characterization of SIPP Cores and DSPE-SIPPs
Transmission electron microscopy (TEM) was used to determine the size and
polydispersity of the particle populations. For SIPP cores, a drop of the hexane
suspension was applied to a carbon-coated grid and dried. For DSPE-SIPPs, a
drop of the aqueous suspension was applied to a carbon-coated grid, dried for 10
minutes, and the excess was absorbed using a kimwipe. Adding a drop of 2%
Uranyl Acetate solution followed by a 2-minute drying period negatively stained
the grid. The excess was removed and the grid was allowed to dry for at least 5
minutes. The samples were imaged on a Hitachi 7500 transmission electron
microscope with an acceleration voltage of 80 kV.

Particle diameters were

calculated using ImageJ Software (30). At least 1000 particles were counted and
the mean Feret diameters and standard deviations were calculated. Diameters of
the DSPE-SIPPs were additionally measured using Dynamic Light Scattering
(DLS) with a Microtrac NanotracTM Ultra DLS (Microtrac, Largo, FL).

The

compositions of the SIPPs, phospholipids, and DSPE-SIPPs were investigated
with thermogravimetric analysis (TGA).
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Aliquots of ODA, SIPP cores,

!

phospholipids, or DSPE-SIPPs were placed in the TGA sample cup and
evaporated at 30 °C under an argon stream for at least 90 minutes until all
solvent had been removed and the mass of the sample stabilized. Weight loss
profiles were then measured with a PyrisTM 1 thermogravimetric analyzer
(PerkinElmer, Waltham, MA) under argon flow. The ODA, phospholipid, and
SIPP content were determined by measuring the mass loss profile while the
temperature was raised from 30 °C to 1000 °C at a 10 °C/min ramp rate.
Inductively coupled plasma-optical emission spectroscopy (ICP-OES) was used
to measure the metal content and iron to platinum ratio of each synthesis. Prior
to analysis, aliquots of the particles were digested at 180 °C with nitric and
hydrochloric acids in a PDS-6 Pressure Digestion System (Loftfields Analytical
Solutions, Neu Eichenberg, Germany). After cooling, the samples were made up
to a known volume, mixed and centrifuged. Samples were then analyzed using a
PerkinElmer Optima 5300DV ICP-OES. The recommended wavelengths for each
of the analytes were used and analysis was performed in an axial mode to
improve detection limits. A blank and set of calibration standards were used to
establish a three-point calibration curve. Calibration and instrument verification
samples were analyzed before and after analyzing the samples, as well as
periodically throughout the measurements. Analyte peaks were examined and
peak identification and background points were adjusted for optimum recoveries.
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Magnetic Characterization of SIPP Cores and DSPE-SIPPs
Superconducting quantum interference device (SQUID) magnetometry was used
to measure the blocking temperatures of the SIPP cores, DSPE-SIPPs, and
MACS® SPIONs and saturation magnetizations of the SIPPs and MACS®
SPIONs.

An aliquot (100 %L) of the samples were applied to the end of cotton

Qtips® (Unilever, Englewood Cliffs, NJ).

Magnetic measurements were then

made on a Quantum Design MPMS-7 SQUID magnetometer.

Temperature

sweeps between 0 and 310 K were performed by zero-field cooling the sample
and then measuring the magnetic moment as a function of temperature under the
influence of a weak magnetic field (1 mT) during warming and subsequent
cooling. This procedure yields both a zero-field-cooled (ZFC) and field-cooled
(FC) curve, respectively. Values of the blocking temperature (
by determining the peak location in each ZFC curve.

) were recorded

Saturation magnetizations

were measured at 310 K (37 °C) by varying the applied field from -5 to 5 Tesla.
Mass magnetizations were calculated from the known iron concentrations
determined by ICP-OES.

Magnetic Resonance Relaxometry
Increasing concentrations of SPIONs (0.08 to 0.48 mM iron) or DSPE-SIPPs
(0.04 to 0.20 mM iron) were added to 1% agarose in 2.0 mL self-standing microcentrifuge tubes (Corning, Corning, NY). Samples were imaged on a 4.7 Tesla
Bruker Biospin (Billerica, MA) MRI system with Paravision 4.0 software.
Samples were imaged with a 256 x 256 matrix, a variable TE, and TR = 10 sec.
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T1 measurements were acquired by inversion-recovery with 15 interpulse delays.
Spin- and gradient echo sequences were used to measure T2, and T2*,
respectively.

The MRI samples were then digested as above and the iron

concentration was determined with ICP-OES. The relaxation rates,

, were

calculated and plotted versus the ICP-OES-determined iron concentration of
each sample. Linear regression was used to fit the data and the relaxivity ( ) of
each sample is given as the slope of the resulting line in units of s-1 mM-1 of iron.

Antibody Conjugation, Cell Culture, and Confocal Binding Assay
Humanized monoclonal antibody against PSMA (J591) (purchased from Neal
Bander, Cornell College of Medicine) and polyclonal goat anti-rabbit IgG (Sigma,
St. Louis, MO) were conjugated to streptavidin in an overnight reaction using a
Lightning-LinkTM Streptavidin Conjugation Kit (Innova Biosciences, Cambridge,
UK) according to the manufacturers’ instructions. Concentrations of streptavidin,
antibodies, and streptavidin-antibody conjugates were quantitated using a
NanoDropTM 2000 Spectrophotometer (Wilmington, DE). Streptavidin-conjugated
antibodies (~30 µg) were then incubated with DSPE-SIPPs (100 µg iron)
overnight at 4 °C to conjugate the antibodies to the DSPE-SIPPs through the
biotin groups of the biotin-DSPE-PEG. A Micro BCATM Protein Assay (Thermo
Scientific, Rockford, IL) was used to quantitate the antibody concentrations and
the amount of antibody conjugated to the DSPE-SIPP surface using a BioSpecmini Spectrophotometer (Shimadzu, Columbia, MD) at a wavelength of 562 nm.
20,000 C4-2 or PC-3 human prostate cancer cells in RPMI media containing 10%
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fetal bovine serum and 100 U/mL Penicillin-Streptomycin solution were seeded
onto polylysine-coated cover slips in 6-well polystyrene plates (Corning, Corning,
NY) and incubated at 37 °C, 5% CO2 for 24 hours.

The media was then

exchanged with media containing J591-DSPE-SIPPs (20 µg iron), IgG-DSPESIPPs (20 µg iron), or PBS (20 µL). The cells were incubated with the particles
for 10 minutes at 37 °C, 5% CO2 and the media was then aspirated and 5.0 mL
PBS was added to wash unbound particles away from the cells. Washing was
repeated 3 times. Cover slips were mounted on slides containing a drop of
ProLong® Gold Antifade Reagent with DAPI (Invitrogen, Eugene, OR).
Confocal Images were acquired using a 60X oil objective with an Olympus IX-81
inverted spinning disk confocal microscope. Cells were also imaged by light
microscopy, using a Zeiss Axiovert 25 CA inverted light microscope with a 63X
phase-contrast objective.

Results and Discussion
SIPP cores and DSPE-SIPPs were prepared as described in the
Experimental Details section. Figure 4.1 shows TEM images of the SIPP cores
and DSPE-SIPPs. The TEM images indicate that both the SIPP cores and the
DSPE-SIPPs are spherical in shape. Using ImageJ software to analyze TEM
images of the SIPP cores and DSPE-SIPPs, we measured average diameters of
8.5 nm ± 1.6 nm and 44.2 nm ± 13.1 nm, respectively. DLS was also employed
to measure the size of the DSPE-SIPPs and revealed diameters of 42.9 nm ± 8.2
nm, showing good agreement with the diameters measured with the TEM
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images. We also used ImageJ to analyze the number of SIPP cores per DSPESIPP. We analyzed 175 DSPE-SIPPs and found that there were 7.2 ± 6.8 SIPP
cores per DSPE-SIPP. The TEM images suggest that the number of SIPP cores

Figure 4.1

TEM and DLS of SIPP Cores and DSPE-SIPPs. TEM images of

(a) SIPP cores and (b, c) DSPE-SIPPs. Scale bars are 20 nm, 50 nm, and 50
nm, respectively. Arrows denote internal areas of the DSPE-SIPPs where space
can be seen between the hydrophobic SIPP cores. (d) DLS of DSPE-SIPPs in
PBS.
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per DSPE-SIPP is quite variable even though the overall encapsulated
population is quite monodisperse, as is evident from the DLS and TEM size
distribution data. Considering that the SIPP cores were found to be 8.5 nm in
diameter, 5 SIPP cores would encompass a diameter of 42.5 nm, which is
approximately the diameter of the DSPE-SIPPs (42.9 nm) and, on average, the
greatest number of SIPP cores we observed spanning the diameter of the DSPESIPPs in the TEM images. This suggests that the DSPE-SIPPs do not contain
an inner aqueous layer characteristic of a liposome, but rather have a purely
hydrophobic inner layer that contains the hydrophobic SIPP cores. DSPE-PEG
phospholipid bilayers are reported to be ~ 5.0 nm in thickness (31).

It is

extremely unlikely that an 8.5 nm hydrophobic SIPP core would fit into a 5 nm
bilayer. Moreover, the TEM images in Figure 4.1 show that there is space in
between the hydrophobic SIPP cores in the inner layer of some of the DSPESIPPs.

It is very unlikely that water would reside at this boundary between

hydrophobic phospholipid tail and hydrophobic ODA on the SIPP core surface.
Therefore, we suggest that the DSPE-SIPPs are not liposomes, but rather
micellar contrast agents.

Johnsson and Edwards (2003) analyzed particles

prepared with increasing concentrations of DSPE and DSPE-PEG and found that
concentrations >33 mole % DSPE-PEG resulted in micelle formation rather than
liposomes. Our DSPE-SIPPs are prepared with ~ 98 mole % DSPE-PEG, and
although liposomes and micelles reported by Johnsson and Edwards (2003) did
not contain an additional hydrophobic superparamagnetic nanoparticle at the
core, their results support the idea of micelle formation in our system. To
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investigate the stability of the DSPE-SIPP micelles, we also used TEM to image
the DSPE-SIPPs up to 21 days post-synthesis. The particles were stored in
PBS, pH 7.4 at 4 °C. The TEM images revealed no physical changes up to 12
days post-synthesis, at which point the DSPE-SIPPs began to merge and
aggregate into larger particles (data not shown).
To investigate the composition of the SIPPs w e used ICP-OES and
measured an iron to platinum ratio (Fe:Pt) of 1.24:1 for the SIPP cores. The
encapsulation process did not appear to significantly affect the Fe:Pt
stoichiometry. To further investigate the composition of the SIPPs and DSPESIPPs, TGA was used to thermally decompose the particles and determine the
weight percents of ODA, phospholipid, SIPP core, and naked FePt.

The

thermograms of ODA, SIPPs, phospholipids, and DSPE-SIPPs are shown in
Figure 4.2. ODA has a boiling point around 314 °C and both ODA and the SIPP
core samples show pronounced weight loss from ~ 180 °C to 375 °C due to the
removal of ODA from the SIPP surface. The hump in the middle of the curve in
Figure 4.2A suggests the SIPP decomposition is a two-step process.

It is

possible that a portion of the ODA is not bound, but rather entrapped and being
removed from the particles before the bound fraction. The TGA results suggest
that the organic ODA layer comprised approximately 72% of the SIPP core mass
and indicated that the SIPPs were 28% naked FePt by mass. The phospholipid
and DSPE-SIPP samples showed similar weight loss profiles and continued to
lose mass up to ~ 400 °C.

The DSPE-SIPP thermogram revealed that the

phospholipids comprised ~ 55% of the DSPE-SIPP mass, while SIPP cores

!

,&!

!

Figure 4.2

SIPP Core and DSPE-SIPP TGA. TGA thermograms of (a) SIPP

cores (solid curve) and ODA (dashed curve) and (b) DSPE-SIPPs (solid curve)
and phospholipids (dashed curve).

Vertical dashed line denotes the

temperature, reported to the left of the dashed line, at which the (a) SIPP cores
and (b) DSPE-SIPPs stopped loosing significant mass. % values are the percent
mass of each sample remaining at the temperature denoted by the vertical
dashed line.
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made up the remaining ~ 45% of the DSPE-SIPP mass. The mass reduction
seen in the thermogram of phospholipids (prepared in chloroform) at ~ 65 °C is
likely due to release of residual chloroform which has a boiling point of 61.2 °C.
To characterize the magnetic properties of the SIPP cores and DSPESIPPs, we used SQUID magnetometry. Figure 4.3 shows the mass
magnetization as a function of the applied magnetic field for the SIPP cores.
Blank Qtips® were also scanned as controls but did not have any measureable
effect in the SQUID (data not shown). The mass magnetization of the SIPP
cores was 120 A m2/kg Fe. As a comparison, we also measured commercially
available SPIONs (~50 nm MACS® MicroBeads, Miltenyi Biotec) that we have
previously used as an MRI contrast agent (32).

The SPIONs had a mass

magnetization of 82 A m2/kg Fe, which is 1.5-fold lower than the SIPPs. SQUID
magnetometry was also used to measure the blocking temperatures of the SIPPs
(Figure 4.3), DSPE-SIPPs, and SPIONs, which were 210 K, 180-210 K, and 155
K (-63 °C, -93 to -63 °C, and -118 °C), respectively.

All of these blocking

temperatures are below body temperature and no hysteresis is seen in the
magnetization curves confirming the SIPPs, DSPE-SIPPs, and SPIONs are
superparamagnetic for biological applications. The broad blocking transition
observed upon lipid encapsulation of the SIPPs is likely caused by the varying
environments of the nanoparticles within the micelle, which alters the effective
anisotropy energy of the particles. It has been shown that packing multiple
magnetic cores into a single particle alters the measured anisotropy of the
particles (33). Next, we calculated the effective anisotropy of the SIPPs and
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Figure 4.3

Magnetization of SIPPs. Saturation magnetization curves for the

mass magnetization of SIPP cores versus the applied magnetic field from -5 to 5
Tesla. Inset shows the zero-field-cooled (ZFC) and field-cooled (FC) curves.
Values of the blocking temperature (TB) were recorded by determining the peak
location in the ZFC curve.
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SPIONs based on the blocking temperatures. The relationship between the
effective anisotropy energy and the blocking temperature is

, where

is Boltzmann’s constant, TB is the blocking temperature, and V is the volume of
the magnetic core in units of m3. The constant 25 is calculated using a relaxation
time of 1 x 10-9 seconds and a measurement time of 100 seconds. Table 4.1
summarizes the physical and magnetic characteristics of the SIPP cores, DSPESIPPs, and SPIONs and shows that the SIPPs effective anisotropy energy is ~ 2fold greater than for the SPIONs. The effective anisotropy constants for the
SIPPs and SPIONs are in excellent agreement with anisotropy constants for
SIPP cores (21,35) and SPIONs (36,37) previously reported.
The DSPE-SIPPs are prepared from a 56:1:1 mole ratio of DSPE-PEG,
biotin-DSPE-PEG, and Liss-Rhod, respectively. The biotin-labeled phospholipid
allowed us to conjugate streptavidin-labeled J591 to the DSPE-SIPPs.

We

measured ~ 2 streptavidin per J591 antibody and after conjugation, we calculated
~ 6 J591 antibodies per J591-DSPE-SIPP. DSPE-SIPPs were also conjugated
to rabbit IgG antibodies as a non-targeted control (IgG-DSPE-SIPPs). We also
measured ~2 streptavidin per IgG antibody, but ~ 12 IgG antibodies were
measured per DSPE-SIPP.

To determine if our J591-DSPE-SIPPs could

specifically target PSMA-expressing human prostate cancer cell lines, we
incubated the J591-DSPE-SIPPs and IgG-DSPE-SIPPs with C4-2 and PC-3
human prostate cancer cells grown on polylysine-coated cover slips. C4-2 cells
were used as our PSMA-positive cell line.

C4-2 is an androgen-deprivation

therapy resistant cell line that over-expresses PSMA (38,39). PC-3 cells were
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Table 4.1

Physical and Magnetic Characterizations of SIPPs, DSPE-SIPPs, and MACS®

Symbol

Variable

Units

SIPP Cores

DSPE-SIPPs

D

Mean Diameter

nm

8.5

42.9

!

Standard Deviation of Diameter

nm

1.6

8.2

---

S

Weight % Solids

%

1.4

1.1

1.0

"

Density

g/cm3

5.2

2.5

2.5

R

Fe:Pt Ratio

---

1.24

1.27

---

CFe

Iron Concentration of Solution

g/mL

1 x 10-3

5 x 10-5

3 x 10-4

C

Concentration of Particles

Particles/mL

3 x 1016

3 x 1014

2 x 1014

TB

Blocking Temperature

K

210

180 - 210

155

K

Effective Anisotropy Energy

J/m3

2.5 x 105

2.5 x 105

µM

Mass Magnetization

A!m2/kg Fe

120

---

a

Hydrodynamic diameter according to manufacturer and (34)

b

Calculated using a magnetic core diameter of 10 nm (34)
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MACS®
a

b

50

1.2 x 105
82
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used as a PSMA-negative cell line. PC-3 cells originate from a bone metastasis,
are androgen-deprivation therapy resistant, and do not express or only minimally
express PSMA (39,40). Figure 4.4 shows the confocal microscopy images of
C4-2 and PC-3 cells incubated with PBS (mock), J591-DSPE-SIPPs, and IgGDSPE-SIPPs. Since the stealth immunomicelles are made with 1 mole % Liss
Rhod, the particles fluoresce red in the confocal images. Both C4-2 and PC-3
cells lacked red fluorescence in the mock samples. Also, both cell lines only
show minimal non-specific or IgG-specific uptake of the IgG-DSPE-SIPPs (non
targeting control). The PSMA-negative cell line, PC-3, also only showed minimal
non-specific or IgG-specific uptake of the J591-DSPE-SIPPs. The amount of
non-specific J591-DSPE-SIPP uptake in the PC-3 cells appears to be
comparable to the non-specific uptake of the IgG-DSPE-SIPPs. In stark contrast
to the other images, significant uptake of the J591-DSPE-SIPPs can be seen in
the C4-2, PSMA-positive cell line. Clearly, J591-DSPE-SIPPs are internalized
only by the C4-2 cell line with only minimal non-specific pick up by the PC-3 cell
line and only minimal non-specific pick up when IgG-DSPE-SIPPs were used.
The confocal data demonstrates the successful targeting of the multifunctional
DSPE-SIPPs and detection of PSMA-expressing human prostate cancer cells in
vitro with no, or minimal, non-specific binding to cell lines that do not express
PSMA.
Finally, to test whether the DSPE-SIPPs could be beneficial as MRI
contrast agents, we measured the longitudinal ( ), transverse (
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Figure 4.4

Specific Detection of PSMA-expressing Prostate Cancer Cells

using J591-DSPE-SIPPs. C4-2 (top row), PSMA-positive, and PC-3 (bottom
row), PSMA-negative, cell lines were imaged using phase-contrast light
microscopy with a 63X objective (a, e). Cells were incubated for 10 minutes with
either PBS (Mock) (b,f), J591-DSPE-SIPPs (c, g), or IgG-DSPE-SIPPs (d, h) and
imaged using confocal microscopy with a 60X oil objective. Blue = DAPI nuclear
stain and Red = Liss Rhod incorporated in the DSPE-SIPPs

!

"#!

!

(

) relaxation rates of the DSPE-SIPPs and commercially available SPIONs.

Table 4.2 shows the relaxivities measured at 4.7 Tesla, while Figure 4.5 shows

Table 4.2
Sample

MR Relaxivities of DSPE-SIPPs and MACS® MicroBeads at
4.7 Teslaa
r1
r2
r2 *
r2/r1

DSPE-SIPPs

17

300

831

18

MACS®

2

23

436

12

MicroBeads
a

Relaxivities are reported as s-1 mM-1

the T2-weighted MR image of the DSPE-SIPP agarose samples, as well as the
transverse relaxation rates of the DSPE-SIPPs and SPIONs as a function of iron
concentration. It is apparent that the DSPE-SIPPs have an ~ 13-fold higher
than the SPIONs, a measure of the particles ability to create negative contrast in
the MR images, and a 1.5-fold increase in the r2/r1 ratio. As expected, the SIPPs
had increased magnetizations compared with the SPIONs and far superior
transverse relaxivities. Since the commercially available SPIONs had such low
transverse relaxivities, we also compared relaxivities of the DSPE-SIPPs with
relaxivities of the clinically used SPION contrast agents Feridex® and Resovist®
that are reported in the literature (21,41-44). Table 4.3 shows the comparison of
the relaxivities at 4.7 Tesla for the DSPE-SIPPs, Feridex®, and Resovist®.
Compared to Feridex® and Resovist®, the DSPE-SIPPs produce superior
negative contrast enhancement in MRI, as is evident from the 1.6- to 3-fold
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Figure 4.5

Magnetic Resonance Relaxometry of DSPE-SIPPs and MACS®

MicroBeads at 4.7 Tesla.

(a) T2-weighted MRI of 1% agarose samples

containing increasing concentrations of DSPE-SIPPs. Top left sample is agarose
that did not contain DSPE-SIPPs.

The other samples have increasing

concentrations of DSPE-SIPPs going from left to right in the top row images and
continuing from left to right in the lower row images. (b) Transverse relaxation
rates (Hz) versus iron concentration (mM) for the DSPE-SIPPs (squares) and
MACS® MicroBeads (triangles). Linear regression was used to fit the data (solid
lines) and the transverse relaxivities (r2) of the DSPE-SIPPs and MACS®
MicroBead SPIONs, given as the slope of the resulting line, were 300.8 ± 8.5 s-1
mM-1and
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23.8

±

6.9

s-1

mM-1,
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respectively.

f

!

Table 4.3

Contrast Agent Relaxivity Comparison at 4.7 Teslaa

Contrast Agent

Coating

Phantom

Diameter [nm]

r1

r2

r2 *

r2/r1

Reference

DSPE-SIPPs

Phospholipid

1% Agarose

42.9

17

300

831

18

Our Data

Feridex®

Dextran

2% Agarose

80-150b

---

148

215

---

(41)

Feridex®

Dextran

2% Agarose

80-150b

---

---

240

---

(44)

Feridex®

Dextran

2% Agarose

80-150b

2.5c

100c

---

33.3

(43)

Feridex®

Dextran

Water

80-150b

40

160

---

4.0

(21)

Feridex®

Dextran

Water

80-150b

2.3

105

---

45.7

(42)

Resovist®

Carbodextran

1% Agarose

60b

2.8

176

---

62.9

(42)

Resovist®

Carbodextran

Water

60b

19.4

186

---

9.6

(21)

a

Relaxivities are reported as s-1 mM-1
(45)
c
Relaxivities are estimated at 200 MHz from the graphs in the supplemental materials
b
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Overall, our data suggest that J591-DSPE-SIPPs are stable,

superparamagnetic, specifically target PSMA-positive human prostate cancer
cells, useful for fluorescence detection for in vitro binding applications, and
superior contrast agents in T2-weighted imaging when compared to both
commercially available and clinically used SPIONs in vitro.

Summary and Conclusions
In 2009, more than 200,000 men were newly diagnosed with and over ~30,000
men died due to prostate cancer in the United States, making carcinoma of the
prostate the second most lethal cancer in men in the United States (1). New
detection methods are critically needed to achieve earlier diagnosis and better
staging of the disease. SPION contrast agents have been used to enhance the
contrast of tumors in MRI, but novel contrast agents with increased relaxivities
could be useful in detecting smaller tumors earlier and with lower doses of the
contrast agents.

Additionally, the specific targeting of contrast agents and

therapeutics to cells of interest is now widely accepted as a cornerstone to the
development of individualized diagnosis and treatment.

Here, we report the

synthesis of SIPP core particles from simple salts and their subsequent
encapsulation in a mixture of phospholipids and conjugation to a monoclonal
antibody against PSMA to produce stable, water soluble, multifunctional contrast
agents with targeting, fluorescent, and MRI capabilities for the specific detection
of prostate cancer cells. To our knowledge this is the first report of the synthesis
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of multifunctional SIPP micelles and the first report of using SIPPs for the specific
detection of prostate cancer.
The SIPP cores have a large effective anisotropy energy of 2.5 x 105 J/m3
and magnetic moment of 120 A m2/kg Fe. We expected that the particles with
higher mass magnetizations would be better contrast agents for MRI. We found
this to be true when comparing the different composition particles. Compared to
the SPIONs, the SIPPs have a higher magnetization accompanied by an ~ 13fold higher transverse relaxivity at 4.7 Tesla. TGA suggests that the particles are
~ 45% SIPP core and ~ 55% phospholipid. The TEM images show that the SIPP
cores and DSPE-SIPPs have diameters of 8.5 nm ± 1.6 and 42.9 nm ± 8.2 nm,
respectively. The DSPE-SIPPs are spherical and contain 7.2 ± 6.8 SIPP cores
per DSPE-SIPP.

These structural characterizations suggest that the DSPE-

SIPPs are micellar contrast agents. Using fluorescence confocal microscopy, we
determined that the J591-DSPE-SIPPs specifically bound to C4-2 human
prostate cancer cells that over-express PSMA and did not bind to PC-3 cells that
do not express PSMA.

Additionally, IgG-DSPE-SIPPs did not accumulate in

either cell line. This shows the specific detection of PSMA-expressing human
prostate

cancer

cells

using

the

fluorescent

capabilities

of

the

SIPP

immunomicelles. Finally, we show that the DSPE-SIPPs were 13-fold better than
commercially available SPIONs and 1.6- to 3-fold better than Feridex® and
Resovist® at producing negative contrast in MRI, at 4.7 Tesla. Taken together,
our data suggest that the multifunctional SIPP immunomicelles are superior
contrast agents for T2-weighted MRI, specifically target PSMA-expressing human
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prostate cancer cells, can be used to specifically detect human prostate cancer
cells in vitro using fluorescence microscopy, and should be beneficial as MRI
contrast agents.

Future studies will include using MRI to specifically detect

human prostate cancer cells in vivo using the SIPP immunomicelles.

It is

important to note that the DSPE-SIPPs could be conjugated to any antibody or
peptide for selective targeting and non-invasive detection of other types of
tumors, using MRI. An additional benefit to this multimodal platform is that the in
vivo biodistribution of the nanoparticles could be measured by examining the
tissues and tumors in vivo and/or ex vivo, using small animal fluorescent imagers
and fluorescence microscopy. Overall, our data suggest that J591-DSPE-SIPPs
specifically target human prostate cancer cells in vitro, can be easily detected
using fluorescence microscopy, and are superior contrast agents in T2-weighted
MRI.
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Abstract
Prominent and unresolved problems with the clinical management of prostate
cancer include the lack of both specific detection methods and efficient
therapeutic interventions.

We report the encapsulation of superparamagnetic

iron platinum nanoparticles (SIPPs) and paclitaxel (PTX) in a mixture of
polyethyleneglycolated

(PEGylated),

fluorescent,

and

biotin-functionalized

phospholipids to create multifunctional SIPP-PTX micelles (SPMs) that were
conjugated to an antibody (J591) against prostate specific membrane antigen
(PSMA) for the specific targeting, magnetic resonance imaging (MRI), and
therapy of human prostate cancer xenografts in mice. These SPMs were 45.4 ±
24.9 nm in diameter and composed of 160.7 ± 22.9 µg/mL iron, 247.0 ± 33.4
µg/mL platinum, and 702.6 ± 206.0 µg/mL PTX. Drug release measurements
showed that, at 37 °C, half of the PTX was released in 30.2 hours in serum and
two times faster in saline. Binding assays suggested that PSMA-targeted SPMs
specifically bound to C4-2 human prostate cancer cells in vitro and released the
PTX into the cells. In vitro, PTX was 2.2 and 1.6 times more cytotoxic than
SPMs to C4-2 cells at 24 and 48 hours incubation, respectively. After 72 hours
of incubation, PTX and SPMs were equally cytotoxic as expected from the
release kinetics. SPMs had MRI transverse relaxivities of 389 ± 15.5 Hz/mM iron
and SIPP-micelles with and without drug caused MRI contrast enhancement in
vivo. Only PSMA-targeted SPMs and PTX significantly prevented growth of C4-2
human prostate cancer xenografts in nude mice. Furthermore, mice injected with
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PSMA-targeted SPMs showed significantly more PTX and platinum in tumors,
compared to non-targeted SPM and PTX injected mice.

Introduction
The continued prevalence, and resistance to treatment, of prostate cancer
in the United States suggests that detection and therapeutic methods must be
improved in order to combat this disease, especially in the deadly, advanced
hormone refractory stage.

As of 2011, prostate cancer remained the most

commonly-detected male cancer in the United States and the second most
common reason for cancer death in men (1).

With over 200,000 newly

diagnosed cases, and in excess of 30,000 mortalities, prostate cancer continued
to be a major burden on the health and financial security of countless men and
families (1-3). After a rapid increase in diagnosed cases in the 1990’s, mostly
due to prostate specific antigen (PSA) testing, the number of newly-diagnosed
cases has plateaued over the past several years. Numerous new therapies have
entered clinical trials in recent years, without a meaningful decline in the number
of mortalities (1,3-7); nevertheless, innovative therapies are clearly required.
Over the past decade significant progress has been made with respect to
the development of novel nanoparticles designed either for the detection or
therapy of cancers (8-14). The most common types of nanoparticles used for the
detection of cancer were fluorescent, radioactive, or superparamagnetic core
nanoparticles that were rendered biocompatible by encapsulation with polymers
or phospholipids (8,12,15,16). Similarly, chemotherapeutic drugs were added to
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the encapsulants with the expectation that more efficacious therapies, with
reduced global toxicity, would result (17-19). These two types of nanoparticles
were typically targeted to primary and/or metastatic tumors either passively by
the enhanced permeation and retention (EPR) effect, which relied on the leaky
vasculature often found in tumors, or through active targeting of specifically overexpressed, or highly-expressed, membrane antigens on the tumor cells or
neovasculature. For this latter purpose, antibodies or peptides were often
conjugated to the surface of the particles (20-22). The development of
nanoparticles that combined these two functions, while highly desirable, had not
received as much attention as was directed towards the synthesis of particles
with separate functions.
Previously, superparamagnetic iron oxide nanoparticles (SPIONs) have
been used as experimental MRI contrast agents to detect cancers (23-26). In
fact, two SPION contrast agents, Resovist® and Feridex®, have been approved
for use by the Food and Drug Administration (FDA) (26,27). Although SPIONs
produce contrast enhancement in MRI, the signal enhancement was often
weaker than that found in radioisotopic imaging modes such as positron emission
tomography (PET) (28).

Therefore, better MRI contrast agents were critically

needed in order to increase signal enhancement for the non-invasive detection of
cancer. We previously reported that SIPPs were superior MRI contrast agents
compared to the more commonly used SPIONs (29,30). For this reason we
chose to use SIPPs as our core magnetic particle for MRI. Additionally, we
previously showed that these SIPP particles could be encapsulated into micelles
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using a mixture of PEGylated phospholipids and that these particles could be
specifically targeted to prostate cancer cell lines, in vitro, using the J591 antiPSMA antibody (30).
Here, we report the synthesis, characterization, and application of
specifically-targeted, multifunctional, superparamagnetic iron platinum particles
(SIPPs) (29) that were encapsulated in a mixture of functionalized phospholipids,
and combined with the chemotherapeutic drug, paclitaxel (PTX). These SIPPs
were subsequently conjugated to a humanized monoclonal antibody (J591)
against prostate specific membrane antigen (PSMA) to produce targeted SIPPPTX micelles (SPMs) for the combined magnetic resonance imaging (MRI)
detection and therapy of prostate cancer. We measured the physical, magnetic,
binding, and cytotoxic properties of the particles in vitro, and the MRI contrast
enhancement, biodistribution, and efficacy in vivo, compared with PTX alone.

Materials and Methods

Materials
Iron

nitrate

nonahydrate

(Fe(NO3)3·9H2O),

Platinum

(II)

acetylacetonate

(Pt(Acac)2), and ODA were purchased from Fisher Scientific (Pittsburgh, PA).
The temperature controller (model 210-J) was purchased from J-KEM Scientific,
Inc. (St. Louis, MO). Heating mantles were purchased from Glas-Col, Llc, (Terre
Haute, IN) and glassware was purchased from Quark Glass (Vineland, NJ). The
phospholipids: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino-
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(polyethyleneglycol)-2000] (DSPE-PEG), DSPE-PEG with biotin conjugated to
the

head

group

(biotin-DSPE-PEG),

and

1,2-dimyristoyl-sn-glycero-3-

phosphoethanolamine-N-[lissamine rhodamine B sulfonyl] (Liss-Rhod) were
purchased from Avanti Polar Lipids (Alabaster, AL). RPMI cell culture media,
fetal bovine serum, and Penicillin-Streptomycin Solution were purchased from
Sigma (St. Louis, MO).

The C4-2 human prostate cancer cell line was a

generous gift from Dr. Marco Bisoffi (UNM). All other chemicals and supplies
were purchased from common manufacturers.

Synthesis of SIPP cores
One mmol Fe(NO3)3·9H2O and 1.0 mmol Pt(Acac)2 were added to 12.5 mmol
ODA in a 25 mL, 3-neck, round-bottom flask fitted with a reflux condenser. The
reaction mixture was heated to 330 °C (at a rate of 200 °C/hr) with 10 °C
recirculated cooling in the reflux condenser.

Refluxing was continued for 45

minutes, at which point the reaction mixture was removed from the heat and
allowed to cool to room temperature. The resulting black particles were collected
in hexane and subjected to repeated washing by collecting the particles in
conical tubes with an external magnet, removing the supernatant, and
resuspending in hexane.

Encapsulation of SIPP cores and Paclitaxel
Phospholipid-encapsulated SIPP cores with and without Paclitaxel (SPMs and
SMs respectively) were prepared using a thin film method. One-half mL of SIPP
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cores (1.4% solids) in hexane was added to a 20.0 mL glass scintillation vial. A
chloroform mixture of (56:1:1 mole ratio) DSPE-PEG, biotin-DSPE-PEG, and
Liss-Rhod was then added to the SIPP cores. In the SPM preparations, 0.4 mL
of 8 mg/mL Paclitaxel in chloroform was also added to the reaction. The mixture
was further diluted in 0.5 mL of methanol and vortexed thoroughly. The vial was
allowed to evaporate under a gentle nitrogen stream in a chemical fume hood to
produce a thin film. 5.0 mL of double-distilled water was heated to 90 °C and
added to the thin film.

Hydration of the thin film was immediate upon brief

vortexing. The hydrated particles were then extruded at 67 °C through an 80 nm
Nucleopore track-etch membrane filter using a mini-extruder (Avanti Polar Lipids,
Alabaster, AL) to produce ~ 45 nm micelles. The SPMs and SMs were then
purified from SIPP-free micelles, excess phospholipids, and drug by collecting
the magnetic particles using an LS magnetic column placed in a VarioMACSTM
magnetic separator (Miltenyi Biotec, Carlsbad, CA).

After the non-magnetic

material had passed through the column, 8.0 mL of double-distilled water was
added to the top of the column to wash the particles. The column was removed
from the magnet and placed in a tube rack with a 2.0 mL glass vial placed
underneath the column. One mL of sterile saline was used to elute the purified
SPMs and SMs from the column. For SPMs and SMs for injections into mice, the
eluted particles were applied to smaller (0.5 mL) µColumns (Miltenyi Biotec,
Carlsbad, CA) and eluted with 200 - 300 µL of sterile saline.
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Physical Characterization of SPMs
Transmission electron microscopy (TEM) was used to determine the size and
polydispersity of the particle populations. For SIPP cores, a drop of the hexane
suspension was applied to a carbon-coated grid and allowed to dry. For SPMs
and SMs, a drop of the aqueous suspension was applied to a carbon-coated grid,
allowed to dry for 10 minutes, and the excess was absorbed using a kimwipe.
Adding a drop of 2% Uranyl Acetate solution followed by a 2-minute drying period
negatively stained the grid. The excess solution was removed and the grid was
allowed to dry for at least 5 minutes. The samples were imaged on a Hitachi
7500 transmission electron microscope with an acceleration voltage of 80 kV.
Particle diameters were calculated using ImageJ Software (31). At least 100
particles were counted and the mean Feret’s diameters and standard deviations
were calculated. Diameters of the SPMs were additionally measured using
Dynamic Light Scattering (DLS) with a Microtrac NanotracTM Ultra DLS
(Microtrac,

Largo,

FL).

Inductively-coupled-plasma,

optical-emission-

spectroscopy (ICP-OES) was used to measure the metal content and iron to
platinum ratio of each synthesis. Prior to analysis, aliquots of the particles were
digested at 180 °C with nitric and hydrochloric acids in a PDS-6 Pressure
Digestion System (Loftfields Analytical Solutions, Neu Eichenberg, Germany).
After cooling, the samples were made up to a known volume, mixed and
centrifuged. Samples were then analyzed using a PerkinElmer Optima 5300DV
ICP-OES. The recommended wavelengths for each of the analytes were used
and analysis was performed in the axial mode to improve detection limits. A
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blank and set of calibration standards were used to establish a three-point
calibration curve. Calibration and instrument verification samples were analyzed
before and after analyzing the samples, as well as periodically throughout the
measurements.

Analyte peaks were examined and peak identification and

background points were adjusted for optimum recoveries.

Magnetic Resonance Relaxometry
Increasing concentrations of SPMs (0 to 400 µM iron) were added to 1% agarose
in 2.0 mL self-standing micro-centrifuge tubes (Corning, Corning, NY). Samples
were imaged on a 4.7 Tesla Bruker Biospin (Billerica, MA) MRI system with
Paravision 4.0 software.

Samples were imaged with a 512 x 256 matrix, a

variable TE, and TR = 10 sec. T1 measurements were acquired by inversionrecovery with 15 interpulse delays. Spin- and gradient-echo sequences were
used to measure T2, and T2*, respectively. The MRI samples were then digested
as above and the iron concentration was determined with ICP. The relaxation
rates, Rn =

1
, were calculated and plotted versus the ICP-determined iron
Tn

concentration of each sample. The relaxivity ( rn ) of each sample is given as the
slope of the linear regression line in units of s-1 mM-1 (Hz/mM) of iron.

Drug Loading Capacity and Drug Release Rates
The amount of Paclitaxel loaded into the particles was quantitated with a
competitive elisa (Cardax Pharmaceuticals, Aiea, HI), according to the
!
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manufacturers instructions. Briefly, a 100 µL aliquot of the SPMs was added to
200 µL of a 1:1 (vol/vol) acetonitrile:methanol mixture.
incubated with occasional vortexing.

The mixture was

After 30 minutes, the solution was

centrifuged at 14,000 rpm for 5 minutes in a tabletop microcentrifuge. Ten-fold
dilutions of the supernatant were prepared in BPT-M buffer (Phosphate buffered
saline (PBS) with 0.25% (w/v) BSA, 0.05% (v/v) Tween-20, 0.02% (w/v) sodium
azide) and 50 µL of each dilution was then subjected to the Elisa in triplicates to
determine the amount of Paclitaxel loaded into the particles.

For the drug

release rate experiments, a 100 µL aliquot of the freshly prepared particles (~ 1.0
mL) was collected as the zero-hour time point. At various subsequent timed
points, the particles were collected on an LS magnetic column placed in a
VarioMACSTM magnetic separator (Miltenyi Biotec, Carlsbad, CA).

The non-

magnetic material flow through (released Paclitaxel) was collected for Elisa
quantitation and the collected particles were then eluted in the original volume of
serum or saline, an aliquot of particles was taken for the Elisa, and the collected
particles were then incubated at 4 °C, 20 °C, or 37 °C until the next timed point.
This routine was repeated until the completion of the experiment; at which time
another 100 µL aliquot of the SPMs was collected. Finally, the zero-hour and
final particle aliquots were added to an equal volume of 1:1 (vol/vol)
acetonitrile:methanol mixture an allowed to incubate for 30 minutes prior to the
PTX Elisa. The amount of Paclitaxel in each well was measured based on a
baccatin III-protein standard curve.
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Antibody Conjugation, cell culture, and confocal binding assay
Humanized monoclonal antibody raised against the extracellular portion of PSMA
(J591) (from Dr. Neal Bander, Cornell College of Medicine) and polyclonal goat
anti-rabbit IgG (Sigma, St. Louis, MO) were conjugated to streptavidin in an
overnight reaction using a Lightning-LinkTM Streptavidin Conjugation Kit (Innova
Biosciences, Cambridge, UK) according to the manufacturers instructions.
Concentrations of streptavidin, antibodies, and streptavidin-antibody conjugates
were quantitated using a NanoDropTM 2000 Spectrophotometer (Wilmington,
DE). Streptavidin-conjugated antibodies (~ 1.0 µg) were then incubated with
SPMs or SMs (~ 150 µg iron) at 4 °C to conjugate the antibodies to the SIPP
micelles through the biotin groups of the biotin-DSPE-PEG.

A Micro BCA™

Protein Assay (Thermo Scientific, Rockford, IL) was used to measure the
antibody concentrations and the amount of antibody conjugated to the micelle
surface using a BioSpec-mini Spectrophotometer (Shimadzu, Columbia, MD) at a
wavelength of 562 nm. Twenty thousand C4-2 human prostate cancer cells in
RPMI 1640 medium containing 10% fetal bovine serum and 100 U/mL PenicillinStreptomycin solution were seeded onto polylysine-coated cover slips in 6-well
polystyrene plates (Corning, Corning, NY) and incubated at 37 °C, 5% CO2 for 24
hours. The medium was then exchanged with medium containing J591-SPMs (~
4.0 µg iron), IgG-SPMs (~ 4.0 µg iron), or PBS (40 µL). The cells were incubated
with the particles for 10 minutes at 4 °C, the media were aspirated off, and 5.0
mL PBS was added to wash unbound particles away from the cells. Washing
was repeated 3 times. Cover slips were mounted on slides containing a drop of
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ProLong® Gold Antifade Reagent with DAPI (Invitrogen, Eugene, OR).
Confocal Images were acquired using an Olympus DSU spinning disk confocal
microscope in the University of New Mexico & Cancer Center Fluorescence
Microscopy Shared Resource: http://hsc.unm.edu/crtc/microscopy/Facility.html.

Cytotoxicity
Five thousand C4-2 cells in 100 µL of RPMI 1640 medium were cultured in 96
well plates. The following day, media were exchanged with 100 µL of media
containing the treatment or controls in increasing concentrations of PTX and
platinum (Pt), determined by measuring the PTX and Pt content of the
preparations using a PTX Elisa and ICP, respectively (vide supra). A WST-1
cytotoxicity kit (a modified MTT Assay from Roche Applied Science) was used to
quantitate the number of metabolically active cells at 24, 48, or 72 hours. The
absorbencies of the samples were normalized to the no-treatment control. Dose
response curves were generated as a function of increasing concentration of
treatment/controls. The dose to inhibit the metabolic activity of 50% of the cells
was determined by non-linear regression.

Animal Experiments
The University of New Mexico International Animal Care and Use Committee
approved all experiments involving animals. 4-6 week old athymic nude mice
had 3 x 106 C4-2 human prostate cancer cells in 50% (vol/vol) Matrigel® (BD
Bioscience, Bedsford, MA) subcutaneously injected into the right flank. The mice
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were monitored and the length, width, and height of the tumors were measured
using a digital caliper. The volumes of the xenografts were determined using the

! 4$
equation V = # & abc . Where V is the tumor volume and a, b, and c are half the
" 3%
length, width, and height, respectively.

Once the xenografts had reached

volumes of 50-100 mm3, they were subjected to MRI and injections of treatments
or controls.

In vivo MRI and injections
Once the xenografts had reached the appropriate volume, mice were
anesthetized using a nose cone that delivered an isoflurane and oxygen mixture
and imaged on a 4.7 Tesla Bruker Biospin (Billerica, MA) MRI system with
Paravision 4.0 software. Mice were imaged with a 256 x 256 pixel matrix with
156 mm pixels and a 40 mm field of view. T1 measurements were acquired with
a TE = 14 msec and a Rapid Acquisition with Relaxation Enhancement with
Variable Repetition Time (RAREVTR) sequence. T2 measurements were
acquired with a TE = 12 msec and a Multi Slice Multi Echo (MSME) sequence.
After the pre-injection imaging, the mice were injected retro-orbitally with 150 µL
of treatments or controls. SIPP-containing injections contained ~200 µg of iron
and 702.6 ± 206 µg of PTX, depending on the preparation. The PTX-only mice
were injected with 400 µg of PTX in a total volume of 150 µL of castor oil and
phosphate buffered saline (PBS). Additionally some mice were not injected with
anything as a “no-injection” control group. After the pre-injection imaging and
subsequent injections, the mice were once again imaged at various timed points
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ranging from 15 minutes to 24 hours post-injection. The T1 and T2 images were
analyzed using ImageJ (30) software.

Regions of interest in the tumor and

muscle were selected and the mean pixel intensity and standard deviations were
recorded at each timed point. Contrast was then calculated as C = (

It ! I m
),
Im

where C is the contrast and It and Im are the pixel intensity in the tumor or
muscle, respectively. The contrast was normalized to the pre-injection images to
produce the contrast (%), calculated as C% = (

Ct
) ! 100 , where Ct and Co are the
Co

contrast of the tumor at the timed point and initial contrast of the tumor in the preinjection image, respectively. Contrast (%) was then plotted verses time postinjection.

Biodistribution and Therapeutic Efficacy
The mice were monitored for 20 days starting on the day of injection with
treatments or controls. The tumor volumes were measured weekly and the mice
were monitored for adverse reactions such as weight loss, infection, paralysis,
and lethargy. On day 20 post-injection, the mice were euthanized using carbon
dioxide-asphyxiation and the tumor and organs were collected and weighed.
Portions of the tumor and organs were then sectioned and again weighed for ICP
and PTX analysis of Pt and PTX content, respectively. The amount of Pt and
PTX was then calculated as percent of the Pt or PTX in the original injection.
The average and standard deviation of Pt and PTX in each group of mice was
then calculated and plotted for each tissue or xenograft to determine the
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biodistribution and amount of targeting. The tumor volumes and mass of each
tumor were compared between each of the groups of treatment and control mice.
Efficacy was measured by decreases in tumor volume in the treatment versus
control groups.

Results
Size and Composition of the SIPP Paclitaxel Micelles (SPMs). Figure 5.1
shows a TEM image of the SPMs. The synthesized SPMs had diameters of 45 ±
25 nm as determined using DLS. This large standard deviation was
representative of the polydispersity that can be seen in the TEM images (Fig.
5.1). The SPMs appeared to fall into two morphological groups. Once group had
multiple, ~9 nm diameter SIPPs (in agreement with our earlier data (23, 30))
encapsulated in the core and were larger in overall diameter (~ 50 nm), whereas
the other group of particles had smaller diameters of 29 ± 2 nm, and appeared to
contain only a single, crystalline 17 ± 2 nm SIPP core encapsulated in the center.
It was important to note that all of these particles were first purified and
separated with a magnetic column; this fact implies that all of the particles in the
TEM image possessed a magnetic SIPP core. It is possible that the smaller
micelles resulted from a reaction between the FePt alloy and PTX, which
generated a crystalline complex between the drug and the alloy.
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Figure 5.1 Transmission electron microscopy image of SPMs. A drop of
SPMs was applied to a carbon-coated grid and allowed to dry. Adding a drop of
2% Uranyl Acetate solution followed by a 2-minute drying period negatively
stained the grid. The excess stain was removed and the grid was allowed to dry
for at least 5 minutes. The samples were imaged on a Hitachi 7500 transmission
electron microscope with an acceleration voltage of 80 kV. The scale bar is 50
nm.
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The metal content of the SPMs was determined using ICP. We compared 4
separate preparations of the SPMs and found that they contained 161 ± 23
mg/mL of iron, 247 ± 33 mg/mL of platinum, and an iron to platinum stoichiometry
of 2.3 ± 0.4, suggesting that our method for making SPMs provided good
reproducibility.

Magnetic Relaxivities of the Micelles. We next compared the relaxivities of
micelles with and without drug using magnetic resonance relaxometry. As
expected from our previous characterizations of the SIPP cores (29,30), SIPP
micelles without PTX (SMs) and SPMs had high transverse relaxivities of r2 = 300
± 12 and 389 ± 16 Hz/mM iron, respectively, making them superior contrast
agents for T2-weighted MRI compared to SPIONs that generally have transverse
relaxivities between 30 and 180 Hz/mM iron (32-35).

PTX Loading of the Micelles. The amount of PTX encapsulated in the SPM
preparations (drug loading capacity) was determined using a PTX competitive
Elisa.

The average drug loading capacity for seven preparations of particles

was 703 ± 206 mg/mL PTX. The high standard deviation suggests that the
amount of PTX incorporated into the micelles was subject to some unknown
variation, perhaps due to phase fractionation, and that other methods of
incorporating the drug into the particles, such as anchoring the drug to the
micelles by conjugating a lipid chain to the drug, may be useful in the future.
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PTX Release from the Micelles. We next aimed to measure how fast the drug
was released from the micelles (drug release rate) in different solutions and at
different temperatures. Figure 5.2 shows the drug release rates for the particles
in serum and saline at 4 °C and 37 °C.

Figure 5.2

Temperature dependence of drug release rates for SPMs in

serum and saline.

A 100 µL aliquot of the freshly prepared particles was

collected as the zero-hour time point. At various subsequent timed points, the
particles were magnetically retained on a column and the amount of PTX in the
non-magnetic flow-through and in the magnetic particles was measured using an
Elisa. The amount of drug release is shown as the percent of drug released
compared to the initial amount of drug loaded into the particles, as measured
with an Elisa immediately after encapsulation. SPMs were incubated in saline at
20 °C (diamonds), saline at 37 °C (squares), serum at 37 °C (circles), or serum at
4 °C (triangles).
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The time at which half of the PTX had been released from the particles (R0.5)
under the different conditions was 19.4 and 14.0 hours for SPMs in saline at 20
°C and 37 °C, respectively. In contrast, the SPMs in serum at 4 °C and 37 °C
had R0.5 times of 38.9 and 30.2 hours, respectively.

It was clear that the drug

was released half as fast in serum (R0.5 ~ 30 hours), compared to saline (R0.5 ~
14 hours) at 37 °C. It has previously been suggested that drugs were released at
different rates from nanoparticles in the presence of different serum proteins (3638) and, therefore, it is possible that serum proteins may be binding to our SPMs
to some extent, causing the drug to be released more slowly due to an increase
in the hydrodynamic diameter of the micelles when protein-bound. An interesting
future study would be to determine what proteins and to what extent these
proteins bind to our PEGylated micelles.

Specific Binding of Antibody-Conjugated Micelles to Prostate Tumor Cells.
We conjugated a fully-humanized monoclonal antibody (J591), raised against the
extracellular portion of PSMA, to our SPMs and measured the specific binding of
the J591-SPMs to C4-2 human prostate cancer cells that express over one
million PSMA receptors on the cell surface (39). Figure 5.3 shows that, compared
to C4-2 cells incubated with non-targeted IgG-SPM control micelles, PSMAtargeted J591-SPMs specifically bound to C4-2 cells. Also of importance is that
the green, fluorescent PTX can also be seen inside of the C4-2 cells that were
specifically targeted and not in the cells that were incubated with IgG-SPMs,
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suggesting not only specific delivery of the contrast agent to the prostate cancer
cells, but also the specific intracellular delivery of the chemotherapeutic drug.

Dapi

SPMs

PTX

Merge

J591SPMs

IgGSPMs

Figure 5.3

Specific binding of J591-SPMs to C4-2 prostate cancer cells.

Confocal images of PSMA-targeted, rhodamine-red-containing SPMs containing
fluorescent PTX (green) (Top Row) and control IgG-SPMs (Bottom Row)
incubated with C4-2 human prostate cancer cells and stained with DAPI. The
last column on the right shows the summed images, which displays all three
colors for the J591-SPMs, and only shows DAPI staining for the IgG-SPMs.
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Comparison of the Cytotoxicity of the SPMs versus PTX Alone. Since the
above results showed that the SPMs specifically bound to, and were taken up by
prostate tumor cells, it was of considerable interest to determine if this
intracellular delivery of the PTX was cytotoxic to the C4-2 cells and to compare
the SPM’s cytotoxicity with that of the SIPP micelles themselves. Figure 5.4
shows the cytotoxicity measurements for our SIPP micelles with and without drug
over the course of 72 hours. The intracellular delivery of PTX by the micelles
was equally cytotoxic to the cells compared to PTX alone after 72 hours of
incubation. However, the PTX alone was somewhat more cytotoxic at 24 and 48
hours, compared to SPMs; the drug concentration to inhibit 50% of the cells
metabolic activity (IC50) at 24 hours was 22 and 50 µM for PTX alone and SPMs,
respectively. At 48 hours the IC50s for PTX and SPMs were 17 and 28 µM drug.
In comparison, by 72 hours both PTX and SPMs had the same IC50 of 0.1 µM
drug.

Thus, in vitro, the PTX was 2.2 and 1.6 times more cytotoxic to the C4-2

prostate cancer cells at 24 and 48 hours, but were equally cytotoxic at 72 hours.
This difference is most likely due to the fact that it takes ~ 30 hours for the drug
encapsulated in the SPMs to escape (Figure 5.2), whereas the non-encapsulated
PTX may begin binding to microtubules faster, in this in vitro setting. The SIPP
micelles in the absence of drug were found to not be cytotoxic to the C4-2 cell
line (Figure 5.4D) using platinum concentrations that were in the same range as
those used in the SPM cytotoxicity experiments.
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SPMs and SIPPs as MRI Contrast Agents. We next produced C4-2 human
prostate cancer xenografts in nude mice and performed MR imaging of the tumor
both pre-injection and post-injection of treatments or controls. Figure 5.5 shows
the T1- and T2-contrast enhancements measured in the tumors as a function of
time, with representative images of an SPM injected tumor. The J591-SPMs and

A

C

B

D

Figure 5.4

Cytotoxicity measurements of PTX, SPMs, and SMs in C4-2

prostate cancer cells. The graphs show C4-2 cell viability measured with a
WST-1 assay after incubation with PTX or SPMs for (A) 24 hours, (B) 48 hours,
and (C) 72 hours. Viability after incubation with SPMs (gray bars) and PTX
(black bars) is shown as the percent of viable cells compared to control samples
not incubated with particles or drug. Panel (D) shows the lack of cytotoxicity
when C4-2 human prostate cancer cells were incubated with SIPP-micelles
without drug (SMs) for 24 hours (black bars) and 48 hours (gray bars).
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pre-injection

Figure 5.5

1 hr post-injection

19 hr post-injection

In vivo MRI and contrast measurements of a mouse bearing a

C4-2 xenograft. Longitudinal (A) and transverse (B) contrast percent measured
for mice bearing C4-2 xenografts and injected with either J591-SPMs (diamond,
solid gray line), J591-SMs (square, dotted gray line), IgG-SPMs (square, dashed
gray line), PTX only (triangle, dashed black line), or nothing (square, solid black
line). Representative T2-weighted MR images of a mouse injected with J591SPMs are shown in (C). The arrows point to areas in the C4-2 xenograft that
showed dark contrast enhancement at one hour post-injection in the middle
frame and an area that still showed contrast enhancement 19 hours postinjection in the far right frame. * Corresponds to a significance of p < 0.05.
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the IgG-SPMs, as well as the J591-SMs, all showed contrast enhancement in T1and T2-weighted MR images of the tumors after injection. The T2 contrast was
more pronounced and was retained in the tumors targeted with J591-SPMs and
J591-SMs, whereas the contrast enhancement in the tumors of mice injected
with non-targeted IgG-SPMs was lost more quickly.

Xenograft Growth Inhibition by SPMs. The tumor volumes of the mice were
measured over time. The data in Figure 5.6 show that only the J591-SPMs and
PTX were able to reduce the volume of tumors in the mice. The non-targeted
IgG-SPMs did not significantly reduce the tumor burden in the animals, nor did
the J591-SMs. None of the mice in the treatment or control groups showed
significant differences in tissue weights or overall body weight over the course of
the experiment (Figures 5.7 and 5.8). In contrast to the J591-SPM injected mice
that showed no adverse effects of the treatment, PTX injected mice suffered from
severe hemorrhaging around the tumor (Figure 5.9), two went blind, and one
mouse was euthanized early due to neurological impairment that was evident
because the mouse continuously circled in the cage and occasionally shook.
Twenty days after the injection of the treatments or controls (or at early
exit timed points for the mice suffering from side effects) the mice were
euthanized and the tumors and tissues were collected to quantify the amount of
PTX and Pt in the tissues. From the data shown in Figure 5.10 it is evident that
the significantly more PTX and Pt was found in the tumors from the J591-SPM
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Figure 5.6

Tumor volume growth curves for nude mice bearing human

C4-2 prostate cancer xenografts treated with various treatments or
controls. (A) Black squares, no treatment controls. (B) Red squares, targeted
SIPPs without drug, showing no effect on tumor growth.

(C) Blue squares,

SIPPs containing PTX conjugated to a control IgG antibody, showing no effect on
tumor growth. (D) Green triangles, PTX alone, without SIPPs, showing the
efficacy of this chemotherapeutic drug by itself.

(E) Purple squares, SIPPs

containing PTX, targeted to PSMA, showing that targeting specifically brings the
drug to the tumors and prevents tumor growth. # corresponds to significance of p
< 0.05.
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Figure 5.7

Tissue weights of mice bearing C4-2 xenografts that were

injected with treatments or controls.

Mice bearing C4-2 xenografts were

injected with J591-SPMs (white bars), J591-SMs (gray bars), IgG-SPMs (blue
bars), PTX alone (beige bars), or nothing (black bars) and 20 days later their
tissues and tumors were collected and weighed.

None of the mice showed

significant differences in tissue weights post-mortem, although the mice injected
with PTX alone, J591-SPMs, and IgG-SPMs showed decreased tumor mass
compared to mice injected with SIPP-micelles without drug and mice that were
not injected. * corresponds to significance of p < 0.05.
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Body weights of mice bearing C4-2 xenografts that were

injected with treatments or controls.

Mice bearing C4-2 human prostate

cancer cell xenografts were injected with the treatments or controls and weighed
on the day of injection and on the day of euthanasia. None of the mice showed
significant differences in loss of body weight over the 20 days.
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A

Figure 5.9

B

Hematoma around the tumors of mice injected with PTX alone.

Representative images are shown for mice injected with PTX alone (A) and
J591-SPMs (B) taken post-mortem. The mice injected with PTX alone clearly
had extensive hematoma around the tumors and all along the right flanks,
whereas the mice injected with J591-SPMs did not have this side effect,
suggesting that in addition to targeting the drug, encapsulation of the drug also
reduced side effects.
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Tissue biodistribution of PTX and platinum in mice bearing

C4-2 xenografts and injected with treatments or controls. Mice were injected
with PTX alone (white bars), J591-SPMs (black bars), or IgG-SPMs (gray bars)
and 20 days post-injection their various organs and tumors were collected and
PTX was measured as percent of the injected dose (A). Significantly more PTX
was measured in the tumors of mice injected with J591-SPMs, compared with
non-targeted SPMs and PTX alone (B). Likewise, the biodistribution of platinum,
from the SIPPs, in the tissues and tumors were measured, using ICP, as percent
of the injected dose (C). Again, significantly more platinum was measured in the
tumors of mice injected with J591-SPMs, compared with non-targeted SPMs and
PTX alone (D).. * and # correspond to significance of p < 0.05 compared to PTX
alone or IgG-SPMs, respectively. ** and ## correspond to significance of p <
0.07 compared to PTX alone or IgG-SPMs, respectively.
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injected mice compared to PTX alone or in the tumors from the IgG-SPM injected
mice. Also, the J591-targeting appeared to have decreased the amount of drug
and particles in the spleen, compared to the IgG-SPMs and additionally
decreased the amount of drug measured in the brains of the mice, compared
with PTX injected mice.

Discussion
Although superparamagnetic iron oxide nanoparticles (SPIONs) are the
most common type of contrast agents used in contrast agent-enhanced magnetic
resonance imaging (MRI), nanoparticles with increased MRI relaxivities are
needed in order to increase the contrast enhancement in MRI applied to various
medical conditions including cancer. We have previously reported that
superparamagnetic iron platinum nanoparticles (SIPPs) are superior contrast
agents for MRI (29,30). The next important step was to determine if the SIPPs
could be beneficial as in vivo imaging agents and to measure any cytotoxicity of
the particles. We have shown both in vitro (Figure 5.4) and in vivo (Figures 5.7,
5.8, 5.9) that the encapsulated iron platinum particles did not have any significant
toxic effects on cells (over 48 hours) or mice (over 20 days). Platinum salts are
known to be toxic (40-42), but the platinum in our particles is metallic and
contained in a crystal structure alloyed with iron. Upon dissociation from the
crystal, the Pt would still be metallic and not in the form of a salt. Pt metal is
chemically inert.
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The biodistribution data (Figure 5.10) for our SIPPs suggested that, except
for the tumors, the platinum was primarily retained in the kidney, spleen, liver,
and lungs. An important point when considering further development of SIPPs
and SPMs for clinical applications was that both platinum and PTX were found in
the feces of the mice 20 days post-injection. This showed that the Pt and PTX
were excreted from the mice in their feces and, although a large percentage of
both metal and drug were retained in the body 20 days post-injection, the Pt and
PTX were eventually eliminated. It would be of interest to perform biodistribution
studies for at least a year to follow the complete excretion of platinum.
Interestingly, both the J591-targeted micelles and the non-targeted IgGmicelle controls caused contrast enhancement in the tumors (Figure 5.5).
Nonetheless, It was clear that the tumors of mice injected with the J591-SPMs
had a higher concentration of both PTX and Pt in the tumors (Figure 5.10). This,
in addition to the fact the contrast enhancement in tumors of IgG-SPM injected
mice was lost more quickly in comparison to J591-SPM mice (Figure 5.5),
suggested that the EPR effect is adequate for bringing the contrast agent into the
tumor for MR imaging. In contrast, the data in Figure 5.6 showed that these IgGSPM injected mice did not undergo a therapeutic response to the non-targeted
treatment. This suggested that, although the concentration of micelles in the
tumors due to the EPR effect was high enough to generate MRI contrast
enhancement, it did not lead to accumulation of enough micelles to prevent
increases in tumor volume over time. It was also possible that the IgG-SPMs
were not endocytosed and, therefore, the drug did not cause cell death because
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it did not reach the cytoplasm.

Paclitaxel was a microtubule stabilizer that

inhibited cell division, leading to cell death (43). The confocal images in Figure
5.3 showed that only the J591-SPMs were internalized into the C4-2 cells in vitro,
whereas the IgG-SPMs were not. This strongly suggested that, in vivo, only the
J591-targeted micelles were able to enter into the cells, where the drug was
released.
In order to cause MRI contrast, the particles must only be attached to the
vasculature and/or cells of the tumor, but in order to cause cell death, the
particles must actually have been taken up by the cells. This could explain some
of the discrepancies seen in the literature relating to the question of whether or
not active targeting works (44). Our data suggested that an important distinction
should be made between whether nanoparticles generated tumor contrast or
were actually therapeutic. Importantly, the growth of the human prostate cancer
xenografts in the nude mice was only inhibited in the mice treated with either
PTX or J591-SPMs. In contrast to the PTX injected mice (Figure 5.9), the J591SPM mice did not suffer from any noticeable side effects or complications over
the 20 days that the mice were followed post-injection.
J591, a monoclonal antibody raised against PSMA, has been used in
numerous clinical trials for prostate cancer (45-50). Our data showed that J591
conjugated to PTX-loaded micelles, specifically targeted the micelles to human
prostate cancer cells and prevented tumor growth in a PSMA-dependent manner.
PSMA is highly expressed in almost all prostate cancer primary and metastatic
tumors (51). Our data suggested that drug-loaded micelles targeted to PSMA
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could successfully treat prostate cancer tumors while possibly reducing the side
effects that commonly seen when using chemotherapeutics alone. Moreover,
PSMA has been shown to be expressed in the neovasculature of almost all solid
tumors, but not in healthy vasculature (51), supporting the idea that PSMAtargeting may be beneficial not only as a prostate cancer targeting motif but as a
general cancer target.

In addition to the specific, targeted killing of PSMA-

positive prostate cancer cells, ours was also the first report on encapsulating
SIPPs with a chemotherapeutic drug in a mixture of functionalized and
fluorescent phospholipids to produce multifunctional, iron platinum, stealth
immunomicelles for the specific MRI and therapy of cancer.
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Chapter 6
Conclusions and future directions

In 2011, more than 200,000 men were newly diagnosed with and over
30,000 men died due to prostate cancer in the United States, making carcinoma
of the prostate the second most lethal cancer in men in the United States (1,2).
Accurate detection methods are important for all aspects of the clinical
management of prostate cancer, including diagnosis, risk assessment, staging,
and prognosis.

Such methods will result in individualized and efficacious

treatments for patients at risk for prostate cancer or for its progression. Many of
these tasks are currently managed by determination of the serum biomarker
prostate specific antigen (PSA). For example, serum PSA levels are used to
evaluate prostate cancer risk and progression, and justify confirmatory biopsies
to diagnose the presence of malignancy. However, biopsies have inherent risks
such as bleeding and infection (3), and cancer is not detected (false negative
cases) in 30-50% of biopsies in patients with subsequently confirmed malignancy
due to small and inconspicuous lesions (4). Another major issue is that ~25% 40% of patients are over-diagnosed using current detection methods leading to
superfluous biopsies (3). These findings indicate that detection and staging of
prostate cancer needs to be improved.
SPIONs are the most common type of contrast agents used in contrast
agent-enhanced MRI (5). Although SPIONs cause negative contrast in the MR
images, the signal enhancement is still lower than other common imaging
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techniques (6). Therefore, novel nanoparticles with increased MRI relaxivities
are needed in order to increase the signal enhancement in MRI and the detection
of cancer, using lower doses of the contrast agents. Additionally, the specific
targeting of contrast agents and therapeutics to cells of interest is now widely
accepted as a cornerstone to the development of individualized diagnosis and
treatment.
The overarching hypothesis of this dissertation is that SIPPs and a
hydrophobic chemotherapeutic drug, paclitaxel, encapsulated in a mixture of
PEGylated, fluorescent-, and biotin-functionalized phospholipids and conjugated
to a monoclonal antibody against PSMA would specifically target prostate cancer
cells, be superior MRI contrast agents for prostate cancer detection (compared to
SPIONs), and have increased therapeutic efficacy in vivo compared to Paclitaxel
alone. This hypothesis was evaluated in four specific aims and the conclusions of
these studies are summarized below, with some possible future directions.
In specific aim one (addressed in Chapter 2), expression differences in
receptor signatures among several human prostate cancer cell lines and
xenografts as a function of tumorigenicity were examined to determine the best
receptor and cell line to use in the nanoparticle targeting studies, both in vitro and
in vivo. Membrane receptors are frequent targets of cancer therapeutic and
imaging agents. However, promising in vitro results often do not translate to in
vivo clinical applications.

Therefore, to better understand this obstacle

messenger RNA and protein expression levels for integrin !"#3, neurotensin
receptor 1 (NTSR1), prostate specific membrane antigen (PSMA), and prostate
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stem cell antigen (PSCA) were measured in LNCaP, C4-2, and PC-3 human
prostate cancer cell lines and in murine xenografts using quantitative reverse
transcriptase

polymerase

chain

reaction,

flow

cytometry,

and

immunohistochemistry. Stable expression patterns were observed for integrin !"
and PSMA in all cells and corresponding xenografts.

Integrin #3 mRNA

expression was greatly reduced in C4-2 xenografts and greatly elevated in PC-3
xenografts compared with the corresponding cultured cells.

NTSR1 mRNA

expression was greatly elevated in LNCaP and PC-3 xenografts. PSCA mRNA
expression was elevated in C4-2 xenografts when compared with C4-2 cells
cultured in vitro. Furthermore, at the protein level, PSCA was re-expressed in all
xenografts compared with cells in culture.
The regulation of mRNA and protein expression of the cell-surface target
proteins !"#3, NTSR1, PSMA, and PSCA, in prostate cancer cells with different
tumorigenic potential, was influenced by factors of the microenvironment,
differing between cell cultures and murine xenotransplants. Integrin !"#3, NTRS1
and PSCA mRNA expression increased with tumorigenic potential, but mRNA
expression levels for these proteins do not translate directly to equivalent
expression levels of membrane bound protein.
Although, it was reasonable to expect that the efficacy of imaging and
therapeutic agents could be improved by using multiple targeting motifs on a
single nanoparticle, because this would markedly increase the affinity of the
nanoparticles for their targets, we found that PSMA was, by far, the most highly
expressed and consistent receptor useful for both in vitro and in vivo studies. As,
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the overarching hypothesis was to promote a novel agent from synthesis,
through in vitro characterizations, all the way to in vivo studies; I determined that
it was best to simply use a single PSMA-targeting motif. Furthermore, the C4-2
cell line had the highest number of PSMA receptors expressed, with over 1.4
million per C4-2 cell, in vitro.

Additionally, xenografts produced using C4-2

human prostate cancer cells produced high amounts of PSMA mRNA and grew
faster than the LNCaP xenografts. Therefore, the C4-2 cell line was chosen as
our model cell line for the subsequent in vitro and in vivo specific aims.
In specific aim two (addressed in Chapters 3 and 4), the synthesis, from
simple salts, and the physical characterization of SIPPs, suitable for use as
contrast agents in MRI, was achieved. The properties of these particles were
determined by means of TEM, TGA, ICP, SQUID magnetometry, and NMR
relaxivity at 4.7 Tesla. TEM showed that the diameters of the particles ranged
from 9.3 nm to 10 nm, depending on the mole ratio of iron to platinum precursors,
and on the concentration of Octadecylamine used in their preparation. The iron
to platinum stoichiometry determined by ICP varied from 1.4:1 to 3.7:1 and was
similarly dependant on the initial mole ratios of iron and platinum salts, as well as
on the concentration of ODA in the reaction. SQUID magnetometry showed that
the SIPPs were superparamagnetic and had magnetic moments that increased
with increasing iron content from 62 to 72 A m2/kg Fe.

The measured

relaxivities of the SIPPs at 4.7 Tesla were higher than commercially available
SPIONs, suggesting that the SIPPs were superior contrast agents for T2weighted MRI.
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In specific aim three (addressed in Chapters 4 and 5), synthesis of SIPPs
and subsequent encapsulation using PEGylated phospholipids to create stealth
immunomicelles (DSPE-SIPPs) that can be specifically targeted to human
prostate cancer cell lines and detected using both MRI and fluorescence imaging
was accomplished. The SIPP cores were optimized and SIPP cores and DSPESIPPs were 8.5 nm ± 1.6 nm and 42.9 nm ± 8.2 nm in diameter. The SIPPs had
a magnetic moment of 120 A m2/kg iron. J591, a monoclonal antibody against
PSMA, was conjugated to the DSPE-SIPPs (J591-DSPE-SIPPs) and specific
targeting of J591-DSPE-SIPPs to PSMA-expressing human prostate cancer cell
lines was demonstrated using fluorescence confocal microscopy. The transverse
relaxivity of the DSPE-SIPPs, measured at 4.7 Tesla, was 300.6 ± 8.5 s-1 mM-1,
which is 13-fold better than commercially available SPIONs (23.8 ± 6.9 s-1 mM-1)
and ~3-fold better than the reported relaxivities for Feridex® and Resovist®. Our
data suggested that J591-DSPE-SIPPs specifically targeted human prostate
cancer cells in vitro, were superior contrast agents in T2-weighted MRI, and could
be detected using fluorescence imaging. To our knowledge, this was the first
report on the synthesis of multifunctional SIPP micelles and their use for the
specific detection of prostate cancer.
Additionally (Chapter 5), I encapsulated the SIPPs with PTX in a mixture
of PEGylated, fluorescent, and biotin-functionalized phospholipids to create
multifunctional SIPP-PTX micelles (SPMs) that were conjugated to the antiPSMA antibody for the specific targeting, MRI, and therapy of human prostate
cancer xenografts in mice. SPMs were 45 ± 25 nm in diameter and composed of
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161 ± 23 µg/mL iron, 247 ± 33 µg/mL platinum, and 703 ± 206 µg/mL PTX. Drug
release measurements showed that, at 37 °C, half of the PTX was released in
30.2 hours in serum and two times faster in saline. Binding assays suggested
that PSMA-targeted SPMs specifically bound to C4-2 human prostate cancer
cells in vitro and released the PTX into the cells. In vitro, PTX was found to be
2.2 and 1.6 times more cytotoxic than SPMs, to C4-2 cells, at 24 and 48 hours
incubation, respectively. At 72 hours incubation PTX and SPMs were equally
cytotoxic. SPMs had MRI transverse relaxivities of 389 ± 15.5 Hz/mM iron.
In specific aim four (Chapter 5), PTX alone or SIPP-micelles with and
without drug were injected in athymic nude mice bearing C4-2 xenografts in their
flanks. We showed, both in vitro and in vivo, that the encapsulated iron platinum
particles did not have any significant toxic effects on cells (over 48 hours) or mice
(over 20 days). Platinum salts were known to be toxic (7-9), but the platinum in
our particles was contained in a crystal structure with iron.

Very similar to

previously reported data for SPIONs, the biodistribution data for our SIPPs
suggested that the platinum that is not targeted to the tumor primarily resides in
the kidney, spleen, liver, and lungs. A crucial point to the further development of
SIPPs for clinical applications was that we found platinum in the feces of the
mice 20 days post-injection. This suggested that the platinum was secreted from
the mice in their feces and not retained for longer periods of time in the tissues.
Interestingly, both the J591-targeted micelles and the non-targeted IgGmicelle controls caused contrast enhancement in the tumors. It was clear that
the tumors of mice injected with the J591-SPMs had a higher concentration of
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both PTX and Pt in the tumors, though. This, in addition to the fact the contrast
enhancement in tumors of IgG-SPM injected mice was quickly lost in comparison
to J591-SPM mice, suggested that the enhanced permeation and retention
(EPR) effect was adequate for bringing the contrast agent into the tumor for MR
imaging.

In contrast, these same IgG-SPM injected mice did not show a

therapeutic response to the non-targeted treatment.

This suggested that

although the concentration of micelles, due to EPR, was enough to cause MRI
contrast enhancement, it did not lead to accumulation of enough micelles to
cause tumor volume reduction. It was also possible that the IgG-SPMs were not
endocytosed and, therefore, the drug could not cause cell death. Confocal
images showed that only the J591-SPMs were internalized into the C4-2 cells in
vitro, whereas the IgG-SPMs were not. This strongly suggested that, in vivo,
only the J591-targeted micelles were able to enter into the cells, where the drug
was released.

In order to cause MRI contrast, the particles must only be

attached to the vasculature and/or cells of the tumor, but in order to cause cell
death, the particles must actually be taken up by the cells. This could explain
some of the discrepancies in the literature of whether active targeting works. It is
important to understand whether the authors were discussing contrast or therapy,
as an important finding in this dissertation is that this is a critical distinction.
Importantly, the human prostate cancer xenografts in the nude mice were
only reduced in mice treated with either PTX or J591-SPMs. In contrast to the
PTX injected mice, the J591-SPM mice did not suffer from any noticeable side
effects or complications over the 20 days that the mice were followed. Our data
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suggested that J591 conjugated to PTX-loaded micelles, specifically targeted the
micelles to human prostate cancer cells and caused reduction in tumor volume in
a PSMA-dependent manner. PSMA is highly expressed in almost all prostate
cancer primary and metastatic tumors (10). Our data suggested that drug-loaded
micelles targeted to PSMA could successfully treat prostate cancer tumors while
possibly

reducing

side

effects

that

are

commonly

seen

when

using

chemotherapeutics alone. In addition to the specific, targeted killing of PSMApositive prostate cancer cells, this dissertation research was novel in that it was
the first report on encapsulating SIPPs with a chemotherapeutic drug in a mixture
of functionalized and fluorescent phospholipids to produce multifunctional, iron
platinum, stealth immunomicelles for the specific MRI and therapy of cancer.
The dissertation offers significant pre-clinical advancement of a new
therapeutic modality for the treatment of early and advanced stage prostate
cancer.

In

addition

to

the

therapeutic

aspect

of

the

project,

the

superparamagnetic component would allow for the detection of prostate cancer
cells, using MRI. This technology would allow for the extraordinary opportunity to
begin treating a tumor at the very instant that it is detected. The interdisciplinary
project was pre-clinical, but conclusions drawn from both the in vitro and in vivo
specific aims provided a strong platform from which the diagnostic and
therapeutic nanoparticles could be optimized for more efficient delivery and
increased efficacy. This research, along with future optimization, should pave
the way for a clinical trial of the therapeutic and diagnostic SIPP micelles. The
ultimate goal in undertaking this pre-clinical research was to reduce death and
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suffering form prostate cancer by providing a non-invasive means to both detect
and treat primary and metastatic prostate cancer.
Several ideas that have been born from this dissertation research warrant
future studies. For one, longer biodistribution studies following the excretion of
platinum are needed. Although, I followed the mice for 20 days post-injection of
the SIPP-micelles without any noticeable side effects, it is plausible that toxic
effects may be seen over a longer time course. Additionally, it is imperative to
determine what amount of the platinum will be excreted and how long (i.e.
months or years) the residual platinum will be retained in the organs. An
interesting future endeavor would be to employ the resources of the
Nanotechnology Characterization Laboratory (NCL). The NCL was developed by
the National Cancer Institute (NCI) to perform preclinical efficacy and toxicity
testing of nanoparticles (http://ncl.cancer.gov). The NCL would send the SIPPmicelles through a battery of in vitro and in vivo cytotoxicity and biocompatibility
characterizations over the course of one year, greatly increasing the rate at
which these particles could possibly be applied in clinical trials.
Another important future study would be to determine if a multifunctional
approach might be required in order to detect and treat advanced tumors that are
characterized by increased heterogeneity of target antigen expression (11). We
have shown (Chapter 2) that the membrane receptor expression profiles of
prostate cancer cells were altered with analogous changes in tumorigenic
potential and that these alterations may comprise signatures of the tumorigenic
state. Moreover, these membrane receptor signatures were altered for in vitro
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and in vivo models. Therefore, targeting nanoparticles, diagnostics, and
therapeutics with multiple antibodies or peptides against PSMA as well as !"#3,
NTSR1, and/or PSCA may be more beneficial in diagnosing and treating early
stage prostate cancer and CRPC than PSMA targeting alone.

Imaging and

therapeutic agents simultaneously directed to multiple targets expressed by
cancer cells should show increased affinities, effectiveness, and specificities
when compared with monofunctional agents. These targeting strategies could be
tested in suitable prostate cancer cell models with well-characterized
phenotypes, such as the human cell lines LNCaP, C4-2, and PC-3, which feature
increasing tumorigenic potential and are widely-used in basic and pre-clinical
research (12,13).
In summary, this research shows that SIPPs can be synthesized using
safer methods than previously described and encapsulated with PTX in a mixture
of

PEGylated,

fluorescent,

and

functionalized

phospholipids

to

create

multifunctional, iron platinum, stealth immunomicelles for the specific detection
and therapy of prostate cancer. These SIPP-micelles were superior to SPIONs
for T2-weighted MRI and prevented prostate cancer xenograft growth, with
comparable efficacy to PTX alone, in a PSMA-dependent manner without
observable side effects.
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